<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Redox Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">Redox Biol</journal-id>
<journal-title-group>
<journal-title>Redox Biology</journal-title>
</journal-title-group>
<issn pub-type="epub">2213-2317</issn>
<publisher>
<publisher-name>Elsevier</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32464501</article-id>
<article-id pub-id-type="pmc">7256645</article-id>
<article-id pub-id-type="publisher-id">S2213-2317(20)30252-4</article-id>
<article-id pub-id-type="doi">10.1016/j.redox.2020.101567</article-id>
<article-id pub-id-type="publisher-id">101567</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The role of nitric oxide in brain disorders: Autism spectrum disorder and other psychiatric, neurological, and neurodegenerative disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="au1">
<name>
<surname>Tripathi</surname>
<given-names>Manish Kumar</given-names>
</name>
</contrib>
<contrib contrib-type="author" id="au2">
<name>
<surname>Kartawy</surname>
<given-names>Maryam</given-names>
</name>
</contrib>
<contrib contrib-type="author" id="au3">
<name>
<surname>Amal</surname>
<given-names>Haitham</given-names>
</name>
<email>Haitham.amal@mail.huji.ac.il</email>
<xref ref-type="corresp" rid="cor1">∗</xref>
</contrib>
<aff id="aff1">Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>∗</label>Corresponding author. <email>Haitham.amal@mail.huji.ac.il</email></corresp>
</author-notes>
<pub-date pub-type="pmc-release">
<day>15</day>
<month>5</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
<pub-date pub-type="collection">
<month>7</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>5</month>
<year>2020</year>
</pub-date>
<volume>34</volume>
<elocation-id>101567</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>2</month>
<year>2020</year>
</date>
<date date-type="rev-recd">
<day>4</day>
<month>5</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 The Authors</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
</license>
</permissions>
<abstract id="abs0010">
<p>Nitric oxide (NO) is a multifunctional signalling molecule and a neurotransmitter that plays an important role in physiological and pathophysiological processes. In physiological conditions, NO regulates cell survival, differentiation and proliferation of neurons. It also regulates synaptic activity, plasticity and vesicle trafficking. NO affects cellular signalling through protein S-nitrosylation, the NO-mediated posttranslational modification of cysteine thiols (SNO). SNO can affect protein activity, protein-protein interaction and protein localization. Numerous studies have shown that excessive NO and SNO can lead to nitrosative stress in the nervous system, contributing to neuropathology. In this review, we summarize the role of NO and SNO in the progression of neurodevelopmental, psychiatric and neurodegenerative disorders, with special attention to autism spectrum disorder (ASD). We provide mechanistic insights into the contribution of NO in diverse brain disorders. Finally, we suggest that pharmacological agents that can inhibit or augment the production of NO as well as new approaches to modulate the formation of SNO-proteins can serve as a promising approach for the treatment of diverse brain disorders.</p>
</abstract>
<kwd-group id="kwrds0010">
<title>Keywords</title>
<kwd>Nitric oxide</kwd>
<kwd>S-nitrosylation</kwd>
<kwd>Autism spectrum disorder</kwd>
<kwd>Alzheimer's disease</kwd>
<kwd>Psychiatry</kwd>
<kwd>Neurodegeneration</kwd>
<kwd>Neurodevelopmental disorders</kwd>
<kwd>Brain disorders</kwd>
<kwd>SHANK3</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1">
<label>1</label>
<title>Introduction</title>
<p id="p0010">Nitric oxide (NO) is one of the most important signalling molecules of the central nervous system (CNS) and peripheral nervous system (PNS) [<xref ref-type="bibr" rid="bib1">[1]</xref>, <xref ref-type="bibr" rid="bib2">[2]</xref>, <xref ref-type="bibr" rid="bib3">[3]</xref>]. NO is produced in the brain from <sc>l</sc>-arginine by three nitric oxide synthase) isoforms (NOS1, NOS2, NOS3) [<xref ref-type="bibr" rid="bib1">1</xref>]. Neuronal NOS (nNOS or NOS1) is constitutively expressed in the cytosol of neurons and requires Ca<sup>2+</sup> for its activity. Inducible NOS (iNOS or NOS2) is found in the cytosol of glial cells and its activity is independent of Ca<sup>2+</sup>. Endothelial NOS (eNOS or NOS3) is constitutively expressed in endothelial cells in the membrane-bound state and requires Ca<sup>2+</sup> for its activity [<xref ref-type="bibr" rid="bib4">[4]</xref>, <xref ref-type="bibr" rid="bib5">[5]</xref>, <xref ref-type="bibr" rid="bib6">[6]</xref>]. nNOS is attached to <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor (NMDAR), post synaptic density protein-95 (PSD-95) and PSD-93 [<xref ref-type="bibr" rid="bib7">7</xref>]. When the NMDAR gets activated by extracellular stimuli, it allows entry of Ca<sup>2+</sup> inside the cell. Ca<sup>2+</sup> can form a complex with calmodulin, and together they initiate the NO formation by activating NOS enzyme [<xref ref-type="bibr" rid="bib8">8</xref>]. NO is a small gaseous molecule, which diffuses to activate guanosine monophosphate (GMP) cyclase (see <xref ref-type="fig" rid="fig1">Fig. 1</xref>). At low concentration, NO acts as a signalling molecule, taking part in the regulation of multiple functions in different organs and systems of the body. In the nervous system, it regulates synaptic activity, plasticity, and vesicle trafficking. However, at higher concentrations, NO may be toxic and could lead to cell death [<xref ref-type="bibr" rid="bib9">9</xref>]. It reacts with superoxide radical (O<sub>2<sup>−</sup></sub>) and forms peroxynitrite, which ultimately damages DNA, lipid and protein during oxidative stress [<xref ref-type="bibr" rid="bib10">10</xref>]. NO may affect cellular signalling through proteins S-nitrosylation (SNO), tyrosine nitration, and S-nitrosoglutathione (GSNO) formation [<xref ref-type="bibr" rid="bib11">[11]</xref>, <xref ref-type="bibr" rid="bib12">[12]</xref>, <xref ref-type="bibr" rid="bib13">[13]</xref>, <xref ref-type="bibr" rid="bib14">[14]</xref>, <xref ref-type="bibr" rid="bib15">[15]</xref>] (see <xref ref-type="fig" rid="fig1">Fig. 1</xref>). SNO is the NO-mediated posttranslational modification (PTM) of cysteine thiols, in which a nitrosogroup is incorporated into a reactive cysteine thiol and forms a nitrosothiol group [<xref ref-type="bibr" rid="bib16">16</xref>,<xref ref-type="bibr" rid="bib17">17</xref>]. SNO plays a role in protein localization, axonal transport, maintenance of synaptic plasticity and regulation of various neuronal pathways [<xref ref-type="bibr" rid="bib9">9</xref>,<xref ref-type="bibr" rid="bib18">18</xref>] (see <xref ref-type="fig" rid="fig1">Fig. 1</xref>). However, dysregulation of NO and SNO signalling is involved in progression of many neurodevelopmental, neurobehavioral and neurodegenerative disorders.<fig id="fig1"><label>Fig. 1</label><caption><p>Schematic representation of NO signalling pathways in physiological conditions. Ca<sup>+2</sup> influx activates nNOS by binding with calmodulin, leading to NO production. NO activates soluble guanylate cyclase to produce cGMP which interacts with many intracellular proteins such as PKG. PKG leads to CREB phosphorylation which leads into transcriptional activation of different genes. NO, directly and indirectly, leads to S-nitrosylation (SNO) of many proteins and receptors. SNO modification of proteins can alter the receptor activity, protein-protein interaction and protein localization leading to alteration in signalling. Increased level of NO increases nitrosative stress, proxynitrite formation, tyrosine nitration of proteins, which ultimately may lead into cell death.</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xlink:href="gr1"></graphic></fig></p>
<p id="p0015">In this review, we summarize the role of NO and SNO in the progression of neurodevelopmental disorders, paying special attention to autism spectrum disorder (ASD). We discuss the involvement of SNO in the pathogenesis of ASD (See <xref ref-type="fig" rid="fig2">Fig. 2</xref>), which we have recently discovered in our studies [<xref ref-type="bibr" rid="bib19">19</xref>]. We have summarize the involvement of NO and SNO signalling in Alzheimer's disease (AD) (<xref ref-type="fig" rid="fig3">Fig. 3</xref>). We also summarize the involvement of NO and SNO signalling in a number of other brain disorders including psychiatric, neurodevelopment, and neurodegenerative ones. Alterations in NO and other NO-related molecular changes in the different brain disorders are described in detailes (<xref ref-type="fig" rid="fig4">Fig. 4</xref>). Further, we list the key SNO-proteins involved in different brain disorders (<xref ref-type="table" rid="tbl1">Table 1</xref>). <xref ref-type="table" rid="tbl2">Table 2</xref> summarizes different pharmacological agents used for therapies by manipulating NO. Finally, we provide mechanistic insight into the contribution of NO in diverse brain disorders and suggest potential and promising therapeutic targets for treatment.<fig id="fig2"><label>Fig. 2</label><caption><p>NO signalling in autism spectrum disorder (ASD). Schematic representation of NO involvement in ASD. Mutation in <italic>SHANK3</italic> gene may cause imbalance in Ca<sup>+2</sup> homeostasis. Ca<sup>+2</sup> is responsible for intracellular NO production which leads to S-nitrosylation of many proteins. S-nitrosylation of calcineurin inhibited its phosphatase activity which leads to increased levels of phosphorylated (P) synapsin-1 and CREB. P-synapsin-1 increases vesicle mobilization and P-CREB increases the recruitment of transcriptional co-activators and cortical activity. S-nitrosylation of syntaxin1a, inhibited its binding with Munc-18 which ultimately leads to increased vesicle docking and fusion.</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xlink:href="gr2"></graphic></fig><fig id="fig3"><label>Fig. 3</label><caption><p>NO signalling in Alzheimer's disease (AD). Schematic representation of the involvement of NO in AD progression. Altered Ca<sup>+2</sup> influx leads into aberrant NO production in cells, which S-nitrosylates many proteins and increases nitrosative stress, peroxynitrite formation, protein tyrosine nitration, which alters the signalling pathways and lead into cell death in AD. SNO of parkin and XIAP alter their E3 ubiquitin ligase activity. SNO of PDI disrupts its chaperone activity which enhances the accumulation of misfolded proteins in cells. SNO of Cdk and DRP-1 alters the mitochondrial dynamics.</p></caption><alt-text id="alttext0020">Fig. 3</alt-text><graphic xlink:href="gr3"></graphic></fig><fig id="fig4"><label>Fig. 4</label><caption><p>The involvement of NO in brain disorders. Alterations in NO and other NO-related molecular changes in the different brain disorders are presented. Abbreviations: NO: nitric oxide; Ntyr: nitrotyrosine; GSNO: S-Nitrosoglutathione; nNOS: neuronal nitric oxide synthase; iNOS: inducible nitric oxide synthase.</p></caption><alt-text id="alttext0025">Fig. 4</alt-text><graphic xlink:href="gr4"></graphic></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>List of S-nitrosylated proteins involved in diverse brain disorders.</p></caption><alt-text id="alttext0030">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Protein</th><th colspan="2">Disease</th><th colspan="2">Sites of SNO modification</th><th>Experimental models</th><th>Suggested molecular/biological consequences of S-nitrosylation</th><th>Reference</th></tr></thead><tbody><tr><td align="left">Calcineurin</td><td align="left" colspan="2">ASD</td><td align="left" colspan="2">–</td><td align="left">Mice</td><td align="left">Inhibition of the phosphatase activity</td><td align="left">[<xref ref-type="bibr" rid="bib19">19</xref>]</td></tr><tr><td align="left">Syntaxin 1a</td><td align="left" colspan="2">ASD</td><td align="left" colspan="2">–</td><td align="left">Mice</td><td align="left">Enhanced binding with SNARE complex</td><td align="left">[<xref ref-type="bibr" rid="bib19">19</xref>]</td></tr><tr><td align="left">mGluR7</td><td align="left" colspan="2">ASD</td><td align="left" colspan="2">–</td><td align="left">Mice</td><td align="left">Increase of Ca<sup>2+</sup> influx in presynaptic neurons</td><td align="left">[<xref ref-type="bibr" rid="bib19">19</xref>]</td></tr><tr><td align="left">RNF213</td><td align="left" colspan="2">AD</td><td align="left" colspan="2">–</td><td align="left">Mice</td><td align="left">Inhibition of the ligase activity</td><td align="left">[<xref ref-type="bibr" rid="bib122">122</xref>]</td></tr><tr><td align="left">Drp1</td><td align="left" colspan="2">AD, HD</td><td align="left" colspan="2">Cys-644</td><td align="left">Human, mice, cell lines</td><td align="left">Increase the rate of mitochondrial fission</td><td align="left">[<xref ref-type="bibr" rid="bib130">130</xref>,<xref ref-type="bibr" rid="bib178">178</xref>]</td></tr><tr><td align="left">Cdk-5</td><td align="left" colspan="2">AD</td><td align="left" colspan="2">Cys-83 and Cys-157</td><td align="left">Human, mice, cell lines</td><td align="left">Hyperactivation of the kinase activity</td><td align="left">[<xref ref-type="bibr" rid="bib125">125</xref>,<xref ref-type="bibr" rid="bib126">126</xref>]</td></tr><tr><td align="left">PSD 95</td><td align="left" colspan="2">AD</td><td align="left" colspan="2">Cys-3 and Cys-5</td><td align="left">Animal, cell lines</td><td align="left">Blocks translocation of the protein</td><td align="left">[<xref ref-type="bibr" rid="bib205">205</xref>]</td></tr><tr><td align="left">IDE</td><td align="left" colspan="2">AD</td><td align="left" colspan="2">Cys-110 and Cys 819</td><td align="left">Cell lines</td><td align="left">Inhibition of the metalloprotease activity</td><td align="left">[<xref ref-type="bibr" rid="bib9">9</xref>,<xref ref-type="bibr" rid="bib18">18</xref>,<xref ref-type="bibr" rid="bib206">206</xref>]</td></tr><tr><td align="left">ApoE</td><td align="left" colspan="2">AD</td><td align="left" colspan="2">Cys-112</td><td align="left">Human, cell lines</td><td align="left">Reduction of affinity to LDL receptors</td><td align="left">[<xref ref-type="bibr" rid="bib136">136</xref>,<xref ref-type="bibr" rid="bib207">207</xref>]</td></tr><tr><td align="left">MEF2</td><td align="left" colspan="2">AD</td><td align="left" colspan="2">Cys-39</td><td align="left">Human, mice, cell lines</td><td align="left">Reduction of the binding affinity to DNA</td><td align="left">[<xref ref-type="bibr" rid="bib41">41</xref>]</td></tr><tr><td align="left">Aldolase C, fructose bisphosphate</td><td align="left" colspan="2">AD</td><td align="left" colspan="2">–</td><td align="left">Human</td><td align="left">Reduction of the metalloprotease activity</td><td align="left">[<xref ref-type="bibr" rid="bib137">137</xref>]</td></tr><tr><td align="left">MAP1B</td><td align="left" colspan="2">AD</td><td align="left" colspan="2">Cys-2457</td><td align="left">Mice, cell lines</td><td align="left">Enhancement of the binding affinity with microtubules</td><td align="left">[<xref ref-type="bibr" rid="bib36">36</xref>,<xref ref-type="bibr" rid="bib208">208</xref>]</td></tr><tr><td align="left">Carbonic anhydrase-II (CAH-II)</td><td align="left" colspan="2">AD</td><td align="left" colspan="2">–</td><td align="left">Human</td><td align="left">Reduction of the enzymatic activity leading to protein accumulation</td><td align="left">[<xref ref-type="bibr" rid="bib209">209</xref>]</td></tr><tr><td align="left">Caspases</td><td align="left" colspan="2">AD</td><td align="left" colspan="2">Cys-163</td><td align="left">Human cell lines</td><td align="left">Decline in protease activity</td><td align="left">[<xref ref-type="bibr" rid="bib9">9</xref>,<xref ref-type="bibr" rid="bib210">210</xref>]</td></tr><tr><td align="left">GSK3β</td><td align="left">AD</td><td align="left" colspan="2">Cys-76, cys-199, cys-317</td><td align="left" colspan="2">Mice, cell lines</td><td align="left">Inhibition of the kinase activity and increased translocation into nucleus</td><td align="left">[<xref ref-type="bibr" rid="bib119">119</xref>]</td></tr><tr><td align="left">XIAP</td><td align="left">PD, AD, HD</td><td align="left" colspan="2">–</td><td align="left" colspan="2">Human, mice, cell lines</td><td align="left">Inhibition of the anti-apoptotic function</td><td align="left">[<xref ref-type="bibr" rid="bib150">150</xref>]</td></tr><tr><td align="left">GAPDH</td><td align="left">AD, ALS, cerebral ischemia, PD</td><td align="left" colspan="2">Cys-150, cys-152</td><td align="left" colspan="2">Human, mice, cell line</td><td align="left">Enhancement of the binding with Siah complex and activation of p300/CBP resulting in the increased neuronal death</td><td align="left">[<xref ref-type="bibr" rid="bib33">33</xref>,<xref ref-type="bibr" rid="bib183">183</xref>,<xref ref-type="bibr" rid="bib184">184</xref>]</td></tr><tr><td align="left">Parkin</td><td align="left">PD</td><td align="left" colspan="2">–</td><td align="left" colspan="2">Human, mice, cell lines</td><td align="left">Autoubiquitination and degradation.</td><td align="left">[<xref ref-type="bibr" rid="bib147">147</xref>,<xref ref-type="bibr" rid="bib152">152</xref>]</td></tr><tr><td align="left">DJ-1</td><td align="left">PD</td><td align="left" colspan="2">Cys-46, cys-53, cys106</td><td align="left" colspan="2">Human, cell lines</td><td align="left">Reduction of the antioxidant activity</td><td align="left">[<xref ref-type="bibr" rid="bib148">148</xref>,<xref ref-type="bibr" rid="bib211">211</xref>]</td></tr><tr><td align="left">PTEN</td><td align="left">PD, AD</td><td align="left" colspan="2">Cys-83</td><td align="left" colspan="2">Human, cell lines</td><td align="left">Reduction of the phosphatase activity</td><td align="left">[<xref ref-type="bibr" rid="bib148">148</xref>]</td></tr><tr><td align="left">PDI</td><td align="left">PD, ALS</td><td align="left" colspan="2">–</td><td align="left" colspan="2">Human, mice, cell line</td><td align="left">Inhibition of the dithiol isomerase activity</td><td align="left">[<xref ref-type="bibr" rid="bib133">133</xref>,<xref ref-type="bibr" rid="bib149">149</xref>]</td></tr><tr><td align="left">Prx2</td><td align="left">PD</td><td align="left" colspan="2">Cys-51, cys-172</td><td align="left" colspan="2">Human, cell lines</td><td align="left">Inhibition of the antioxidant activity</td><td align="left">[<xref ref-type="bibr" rid="bib151">151</xref>]</td></tr><tr><td align="left">Huntingtin</td><td align="left">HD</td><td align="left" colspan="2">–</td><td align="left" colspan="2">Mice, cell lines</td><td align="left">Protein aggregate formation leading to cell death</td><td align="left">[<xref ref-type="bibr" rid="bib174">174</xref>]</td></tr><tr><td align="left">NMDAR</td><td align="left">AD, Prion disease</td><td align="left" colspan="2">Cys −744, cys-798</td><td align="left" colspan="2">Animal</td><td align="left">Inhibition of the receptor activity and NO production</td><td align="left">[<xref ref-type="bibr" rid="bib9">9</xref>,<xref ref-type="bibr" rid="bib18">18</xref>,<xref ref-type="bibr" rid="bib212">212</xref>]</td></tr><tr><td align="left">MMP9</td><td align="left">Cerebral ischemia</td><td align="left" colspan="2">–</td><td align="left" colspan="2">Animal, cell lines</td><td align="left">Reduction of the metalloprotease activity</td><td align="left">[<xref ref-type="bibr" rid="bib213">213</xref>]</td></tr><tr><td align="left">PLP</td><td align="left">MS</td><td align="left" colspan="2">–</td><td align="left" colspan="2">Animal</td><td align="left">Conformational and functional alteration</td><td align="left">[<xref ref-type="bibr" rid="bib195">195</xref>,<xref ref-type="bibr" rid="bib204">204</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Summarization of different pharmacological agents used for therapies by manipulating NO.</p></caption><alt-text id="alttext0035">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Disease name</th><th>Pharmacological agents</th><th>Protective versus detrimental effects</th><th>References</th></tr></thead><tbody><tr><td align="left">Schizophrenia</td><td align="left">Sodium nitroprusside</td><td align="left">Improvement in attention, cognitive and working memory</td><td align="left">[<xref ref-type="bibr" rid="bib68">68</xref>,<xref ref-type="bibr" rid="bib69">69</xref>]</td></tr><tr><td align="left">Bipolar disorder</td><td align="left">Lithium</td><td align="left">Increased NO level in plasma and improved symptoms.</td><td align="left">[<xref ref-type="bibr" rid="bib76">76</xref>]</td></tr><tr><td align="left">Migraine</td><td align="left"><list id="olist0010" list-type="simple"><list-item id="o0010"><label>1</label><p id="p0155">Sodium nitroprusside</p></list-item><list-item id="o0015"><label>2</label><p id="p0160">Isosorbide dinitrite</p></list-item><list-item id="o0020"><label>3</label><p id="p0165">Sildenafil</p></list-item><list-item id="o0025"><label>4</label><p id="p0170">Mepyramine</p></list-item></list></td><td align="left"><list id="olist0015" list-type="simple"><list-item id="u0010"><p id="p0175">1-Initiated headache and migraine</p></list-item><list-item id="o0030"><label>2</label><p id="p0180">Initiated migraine</p></list-item><list-item id="o0035"><label>3</label><p id="p0185">Increased migraine pain</p></list-item><list-item id="o0040"><label>4</label><p id="p0190">Reduced headache</p></list-item></list></td><td align="left">[<xref ref-type="bibr" rid="bib87">[87]</xref>, <xref ref-type="bibr" rid="bib88">[88]</xref>, <xref ref-type="bibr" rid="bib89">[89]</xref>,<xref ref-type="bibr" rid="bib94">[94]</xref>, <xref ref-type="bibr" rid="bib95">[95]</xref>, <xref ref-type="bibr" rid="bib96">[96]</xref>]</td></tr><tr><td align="left">Epilepsy</td><td align="left"><list id="olist0020" list-type="simple"><list-item id="u0015"><p id="p0195">1-Methylene blue</p></list-item><list-item id="o0045"><label>2</label><p id="p0200"><sc>l</sc>-arginine</p></list-item><list-item id="o0050"><label>3</label><p id="p0205"><sc>l</sc>-NAME</p></list-item></list></td><td align="left"><list id="olist0025" list-type="simple"><list-item id="u0020"><p id="p0210">1-Increased symptoms of epilepsy</p></list-item><list-item id="o0055"><label>2</label><p id="p0215">Reduced symptoms of epilepsy</p></list-item><list-item id="o0060"><label>3</label><p id="p0220">Induced seizures</p></list-item></list></td><td align="left">[<xref ref-type="bibr" rid="bib99">99</xref>,<xref ref-type="bibr" rid="bib100">100</xref>,<xref ref-type="bibr" rid="bib102">102</xref>,<xref ref-type="bibr" rid="bib103">103</xref>]</td></tr><tr><td align="left">Addiction</td><td align="left"><list id="olist0030" list-type="simple"><list-item id="u0025"><p id="p0225">1-<sc>l</sc>-NAME</p></list-item><list-item id="o0065"><label>2</label><p id="p0230">L-NNA</p></list-item><list-item id="u0030"><p id="p0235">3-Tempol</p></list-item></list></td><td align="left"><list id="olist0035" list-type="simple"><list-item id="o0070"><label>1</label><p id="p0240">Reduced morphine abstinence syndrome</p></list-item><list-item id="u0035"><p id="p0245">2-Reduced opioid withdrawal syndrome</p></list-item><list-item id="u0040"><p id="p0250">3-Abolished cocaine psychomotor sensitization</p></list-item></list></td><td align="left">[<xref ref-type="bibr" rid="bib108">[108]</xref>, <xref ref-type="bibr" rid="bib109">[109]</xref>, <xref ref-type="bibr" rid="bib110">[110]</xref>,<xref ref-type="bibr" rid="bib112">112</xref>]</td></tr><tr><td align="left">AD</td><td align="left">L-NNA</td><td align="left">Reduced apoptosis</td><td align="left">[<xref ref-type="bibr" rid="bib126">126</xref>]</td></tr><tr><td align="left">PD</td><td align="left"><list id="olist0040" list-type="simple"><list-item id="u0045"><p id="p0255">1-7 -nitroindazole</p></list-item><list-item id="o0075"><label>2</label><p id="p0260">Pargyline</p></list-item><list-item id="o0080"><label>3</label><p id="p0265"><sc>l</sc>-NAME</p></list-item><list-item id="o0085"><label>4</label><p id="p0270">GW274150</p></list-item></list></td><td align="left"><list id="olist0045" list-type="simple"><list-item id="u0050"><p id="p0275">1-Protection from cell death</p></list-item><list-item id="o0090"><label>2</label><p id="p0280">Protection from cell death</p></list-item><list-item id="o0095"><label>3</label><p id="p0285">Protection from cell death</p></list-item><list-item id="o0100"><label>4</label><p id="p0290">Reduced microglial activation, cytokine and NO production</p></list-item></list></td><td align="left">[<xref ref-type="bibr" rid="bib164">[164]</xref>, <xref ref-type="bibr" rid="bib165">[165]</xref>, <xref ref-type="bibr" rid="bib166">[166]</xref>, <xref ref-type="bibr" rid="bib167">[167]</xref>,<xref ref-type="bibr" rid="bib170">170</xref>]</td></tr><tr><td align="left">ALS</td><td align="left"><list id="olist0050" list-type="simple"><list-item id="o0105"><label>1</label><p id="p0295">Deprenyl</p></list-item><list-item id="o0110"><label>2</label><p id="p0300">Diethyl NONOate</p></list-item><list-item id="o0115"><label>3</label><p id="p0305">L-NNA</p></list-item></list></td><td align="left"><list id="olist0055" list-type="simple"><list-item id="o0120"><label>1</label><p id="p0310">Reduced apoptosis</p></list-item><list-item id="o0125"><label>2</label><p id="p0315">Reduced cell death</p></list-item><list-item id="o0130"><label>3</label><p id="p0320">Reduced aggregates formation</p></list-item></list></td><td align="left">[<xref ref-type="bibr" rid="bib183">183</xref>,<xref ref-type="bibr" rid="bib185">185</xref>,<xref ref-type="bibr" rid="bib191">191</xref>]</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="sec2">
<label>2</label>
<title>Role of nitric oxide in neuronal development</title>
<p id="p0020">NO plays major roles in neurogenesis and neurodevelopment [<xref ref-type="bibr" rid="bib20">20</xref>]. Importantly, NO regulates the activity of the brain-derived growth factor (BDNF) [<xref ref-type="bibr" rid="bib21">21</xref>]. BDNF promotes SNO of many nuclear proteins, including those related to the cAMP response element-binding protein (CREB), a cellular transcription factor that is involved in regulation of neuronal and dendritic development [<xref ref-type="bibr" rid="bib22">22</xref>]. Sen and Snyder [<xref ref-type="bibr" rid="bib23">23</xref>] have shown that BDNF, along with other nerve-growth factors, activate nNOS leading to S-nitrosylation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH)/seven in absentia (Siah) homolog complex (SNO-GAPDH-Siah). SNO of GAPDH at Cys-150 promotes its association with Siah, which leads to formation of SNO-GAPDH-Siah complex. Further, SNO-GAPDH-Siah complex translocate into the nucleus [<xref ref-type="bibr" rid="bib24">24</xref>], initiating the ubiquitination and degradation of the histone-methyltransferase enzyme, suppressor of variegation 3–9 homolog 1 (SUV39H1) protein. SUV39H1 is the principal enzyme responsible for trimethylation of histone H3 at Lys-9, a molecular marker associated with transcriptional silencing. Therefore, inhibition of the trimethylation of histone H3 via SUV39H1 degradation enhances the binding and activation of CREB [<xref ref-type="bibr" rid="bib23">23</xref>]. In conjunction with BDNF-induced SNO, CREB binds to the cAMP response element of the promoters of its target genes upon phosphorylation at Ser-133 in the KID domain [<xref ref-type="bibr" rid="bib25">25</xref>] by different receptor-activated protein kinases, such as protein kinase A (PKA), calmodulin-dependent protein kinase (CaMK), mitogen-activated protein kinases (MAPK), and other kinases. These kinases are activated by Ca<sup>2+</sup> influx triggered upon depolarization [<xref ref-type="bibr" rid="bib26">26</xref>,<xref ref-type="bibr" rid="bib27">27</xref>]. The phosphorylation of Ser-133 leads to a 10- to 20-fold increase in CREB's transcriptional activity [<xref ref-type="bibr" rid="bib28">28</xref>]. Interestingly that both NO signalling, which produces cGMP, and cAMP signalling could regulate the phosphorylation of CREB (see <xref ref-type="fig" rid="fig1">Fig. 1</xref>). cAMP activates CREB through the canonical cAMP/PKA pathway and the exchange protein directly activated by cAMP (Epac) pathway. Epac activates extracellular signal-regulated kinase 1/2 (ERK1/2) signalling, which subsequently leads to Ser-133 phosphorylation of CREB [<xref ref-type="bibr" rid="bib29">29</xref>]. Meanwhile, cGMP activates the downstream protein cGMP-dependent protein kinase G (PKG), which also phosphorylates the transcription factor CREB at Ser-133 [<xref ref-type="bibr" rid="bib29">29</xref>]. This dual phosphorylation by cAMP/PKA/Epac and cGMP/PKG pathways may amplify the CREB activity [<xref ref-type="bibr" rid="bib29">29</xref>]. Once CREB is activated and CREB-binding protein is recruited, transcription is initiated [<xref ref-type="bibr" rid="bib30">30</xref>].</p>
<p id="p0025">Further, under normal NO concentration, SNO-GAPDH-Siah translocation is negatively regulated by GAPDH's competitor of Siah protein enhancer life (GOSPEL) protein. SNO of GOSPEL at Cys-47 enhances its ability to bind to GAPDH, which terminates the translocation of SNO-GAPDH-Siah complex. SNO-GAPDH-GOSPEL remains in the cytosol [<xref ref-type="bibr" rid="bib31">31</xref>]. In contrast, nuclear translocation of SNO-GAPDH promotes transnitrosylation of many proteins, such as histone deacytylase 2 (HDAC2), DNA-activated protein kinase, sirtulin −1, and others [<xref ref-type="bibr" rid="bib32">32</xref>,<xref ref-type="bibr" rid="bib33">33</xref>]. BDNF-induced transnitrosylation reaction between SNO-GAPDH and HDAC2 results in SNO of HDAC2 at Cys-262 and Cys-274 [<xref ref-type="bibr" rid="bib34">34</xref>]. Normally, HDAC2 remains attached to CREB target gene promoters. However, SNO of HDAC2 promotes its dissociation and rapid acetylation of histone H3 and H4, resulting in association of CREB with its target genes. Consequently, BDNF-mediated SNO of HDAC2 plays a role in dendritic development [<xref ref-type="bibr" rid="bib32">32</xref>,<xref ref-type="bibr" rid="bib34">34</xref>].</p>
<p id="p0030">Rearrangement of actin and myosin in cytoskeletons is necessary for axonal growth, axonal guidance, axonal modification and brain development [<xref ref-type="bibr" rid="bib20">20</xref>] and these processes are also mediated by NO [<xref ref-type="bibr" rid="bib35">35</xref>]. Furthermore, SNO of microtubule-associated protein B1 (MAPB1) leads to a modification of axon retraction [<xref ref-type="bibr" rid="bib36">36</xref>]. MAPB1 contains a heavy chain (HC) and a light chain (LC1) domains. LC1 domain can be S-nitrosylated at Cys-2657 of MAPB1, which increases the binding capacity of HC/LC1 MAPB1 complex with microtubules. This complex inhibits the dynein leading to inhibition of axonal extension and increases of axonal retraction [<xref ref-type="bibr" rid="bib36">36</xref>].</p>
<p id="p0035">Previous work has shown the involvement of NO in neurogenesis [<xref ref-type="bibr" rid="bib37">[37]</xref>, <xref ref-type="bibr" rid="bib38">[38]</xref>, <xref ref-type="bibr" rid="bib39">[39]</xref>]. nNOS knockout rats or inhibition of nNOS by pharmacological agents negatively regulate neurogenesis [<xref ref-type="bibr" rid="bib37">[37]</xref>, <xref ref-type="bibr" rid="bib38">[38]</xref>, <xref ref-type="bibr" rid="bib39">[39]</xref>]. Thus, SNO of myocyte enhancer factor 2 (MEF2), a transcription factor involved in neurogenesis at Cys-39 reduces its binding affinity to DNA and ultimately inhibits its transcriptional activity [<xref ref-type="bibr" rid="bib40">40</xref>]. SNO-MEF2 also reduces the expression of nuclear receptor tailess (TLX) [<xref ref-type="bibr" rid="bib41">41</xref>], which is a regulator of adult neurogenesis and is responsible for learning and memory [<xref ref-type="bibr" rid="bib42">42</xref>]. Lipton and co-workers have found high level of SNO-MEF2 in Alzheimer's disease (AD), leading to neurodegeneration. These changes were present in the post-mortem brains and mutant transgenic mice [<xref ref-type="bibr" rid="bib41">41</xref>]. Thus, SNO-MEF2 inhibits neurogenesis and neuronal differentiation in brain [<xref ref-type="bibr" rid="bib41">41</xref>]. Studies on nNOS knockout mice showed abnormal dendritic branching [<xref ref-type="bibr" rid="bib43">43</xref>] and reduction in neurogenesis [<xref ref-type="bibr" rid="bib37">37</xref>]. All these reports imply that NO plays an important role in neurodevelopment. Thus, dysregulation of the NO signalling can bring about a variety of neurodevelopmental diseases. Below, we discuss the role of NO in different brain disorders.</p>
</sec>
<sec id="sec3">
<label>3</label>
<title>Autism spectrum disorder (ASD)</title>
<p id="p0040">ASD is a neurodevelopmental disorder associated with impaired communication, impaired social skills and repetitive behaviour [<xref ref-type="bibr" rid="bib44">44</xref>]. ASD is caused by genetic mutations, as well as environmental and non-genetic factors [<xref ref-type="bibr" rid="bib45">45</xref>]. According to the world health organization (WHO), 1–1.5% of children suffer from ASD globally [<xref ref-type="bibr" rid="bib46">46</xref>,<xref ref-type="bibr" rid="bib47">47</xref>]. Currently, there is no treatment for ASD and symptomatic features are reduced by different psychiatric medications.</p>
<p id="p0045">SHANK3 mutation is one of the most promising ASD-associated mutations [<xref ref-type="bibr" rid="bib48">48</xref>]. Several reports on <italic>Shank3</italic> KO mouse models showed defects in biochemical, electrophysiological and cellular pathways [<xref ref-type="bibr" rid="bib49">[49]</xref>, <xref ref-type="bibr" rid="bib50">[50]</xref>, <xref ref-type="bibr" rid="bib51">[51]</xref>]. As per our knowledge, Amal et al. was the first to report the involvement of NO in the development of ASD [<xref ref-type="bibr" rid="bib19">19</xref>]. Amal et al. has hypothesized that <italic>Shank3</italic> mutation leads to an increase of Ca<sup>2+</sup> influx that in turn activates nNOS activity leading to the dramatic NO formation and NO-related molecular changes, including S-nitrosoglutathione (GSNO), 3-nitrotyrosine (Ntyr), and SNO [<xref ref-type="bibr" rid="bib19">19</xref>]. SNO targets a wide range of prominent intracellular proteins leading to alteration in signalling pathways, which may converge onto synaptic, neuronal and behavioral deficits. The work has reported that in <italic>Shank3</italic> mutated mice [InsG3680 (+/+)], the SNO-proteome is reprogrammed and dysregulation of proteins by S-nitrosylation and de-nitrosylation occurs [<xref ref-type="bibr" rid="bib19">19</xref>]. System biology analysis of both wild type (WT) and <italic>Shank3</italic> KO mice revealed 9-fold change in SNO level of proteins involved in the synaptic vesicle cycle (Syntaxin1a (Stx1a), synaptotagmin 1, and N-ethylmaleimide sensitive fusion protein (Nsf)) in cortex of KO mice but not in WT mouse brain. Gene ontology (GO) and KEGG analysis of 6-week-old KO mice showed enrichment of many proteins that involved in neurodevelopment and ASD. Further, systems biology analysis showed the enriched SNO proteins involved in synaptic vesicle cycle and oxidative phosphorylation in <italic>Shank3</italic> KO mice. These results convincingly show an association between S<italic>hank3</italic> mutation and NO [<xref ref-type="bibr" rid="bib19">19</xref>]. Further, this work showed that protein-protein interaction analysis in the cortex of KO mice showed a network of S-nitrosylated proteins functionally involved in synaptic vesicle cycle, neurotransmission (protein phosphatase catalystic subunit alpha-Ppp3ca, syntaxin 1a, vesicle associated membrane protein 3 and others) and in glutamatargic pathway (glutamate dehydrogenase 1, mGluR, G protein subunit alpha O1 Gnao-1 and others) [<xref ref-type="bibr" rid="bib19">19</xref>]. Analyzing the shared SNOed proteins in the cortex of KO mice of both 6-week-old and 4-month-old mice showed an evidence of enriched processes known to be affected in ASD, such as synaptic vesicle cycle. The interactome analysis of the shared proteins in the cortex of KO mice showed protein clusters that function in the synaptic vesicle cycle (syntaxin 1a, Ppp3ca, Nsf and Dnm1) and glutamate regulation (glutamic-oxaloacetic transaminase-Got1, Got2, Gnao-1). This work showed an increase of 3-nitrotyrosine level in different cortical regions. Level of GSNO was found to be increased in the cortex of both KO groups as compared with WT groups. The study also showed that calcineurin was SNOed in the cortex which inhibited its phosphatase activity (see <xref ref-type="table" rid="tbl1">Table 1</xref> and <xref ref-type="fig" rid="fig2">Fig. 2</xref>). Inhibition of calcineurin activity increased the levels of <italic>p</italic>-Synapsin-1 and <italic>p</italic>-CREB protein [<xref ref-type="bibr" rid="bib19">19</xref>], (see <xref ref-type="fig" rid="fig2">Fig. 2</xref>). Synapsin-1 is involved in regulation of vesicle exocytosis and its phosphorylation increases exocytosis of vesicles [<xref ref-type="bibr" rid="bib52">52</xref>]. Increase in phosphorylated level of Synapsin-1 in the cortex of the mutant mice may indicate that SNO of calcineurin is responsible for increased vesicle mobilization. The study found a significant increase in <italic>p</italic>-CREB levels, which is another substrate of calcineurin [<xref ref-type="bibr" rid="bib19">19</xref>]. Increased level of <italic>p</italic>-CREB has also been reported in another model of ASD [<xref ref-type="bibr" rid="bib53">53</xref>]. Syntaxin1a, which enhances the formation of the SNARE complex, was SNOed in <italic>Shank3</italic> KO mice [<xref ref-type="bibr" rid="bib19">19</xref>]. SNO of this protein enhances the formation of the SNARE complex leading to increase of synaptic vesicle docking and fusion [<xref ref-type="bibr" rid="bib54">54</xref>], (see <xref ref-type="fig" rid="fig2">Fig. 2</xref>). SNO of metabotropic glutamate receptor 7 (mGluR7) was found in the cortex of the mutant mice. The study suggested that SNO of mGlur7 may increase the influx of Ca<sup>2+</sup> in presynaptic neurons, which in turn increases vesicle fusion [<xref ref-type="bibr" rid="bib19">19</xref>]. Taken together, the study implies that NO is an important factor in ASD. The insights obtained from the <italic>SHANK3</italic> mutation study may likely be applicable to a broader group of patients with genetically diverse but mechanistically related etiology, thus it may imply NO as an important pathological factor in ASD.</p>
</sec>
<sec id="sec4">
<label>4</label>
<title>Schizophrenia</title>
<p id="p0050">Schizophrenia is a severe and chronic mental disorder, that affects person's thinking, feeling, and behaviour. It accounts for approximately 1% of the total world population [<xref ref-type="bibr" rid="bib55">55</xref>]. The cause of schizophrenia is unknown and it is considered as a multifactorial disorder [<xref ref-type="bibr" rid="bib56">56</xref>]. Symptoms of schizophrenia can be divided into three different categories, such as positive symptoms, negative symptoms and cognitive disturbances [<xref ref-type="bibr" rid="bib56">56</xref>,<xref ref-type="bibr" rid="bib57">57</xref>]. Hallucinations, catatonic behaviour, delusion and disturbed thought procession are considered as positive symptoms. Avolition, anhedonia and social withdrawal represent negative symptoms [<xref ref-type="bibr" rid="bib55">55</xref>]. Studies suggested that NO may play a role in the development of schizophrenia [<xref ref-type="bibr" rid="bib58">58</xref>,<xref ref-type="bibr" rid="bib59">59</xref>]. Researchers hypothesized that impairments of dopaminergic and cholinergic pathways may be involved in the development of schizophrenia through the involvement of NMDA receptors-dependent NO signalling [<xref ref-type="bibr" rid="bib60">[60]</xref>, <xref ref-type="bibr" rid="bib61">[61]</xref>, <xref ref-type="bibr" rid="bib62">[62]</xref>]. Polymorphism of nNOS gene is found to be a critical risk factor for the development of schizophrenia [<xref ref-type="bibr" rid="bib63">63</xref>]. Also, the levels of NO metabolites, such as nitrite and nitrate, were found to be reduced in plasma, serum and cerebrospinal fluid (CSF) of schizophrenic patients (see <xref ref-type="fig" rid="fig4">Fig. 4</xref>) [<xref ref-type="bibr" rid="bib64">[64]</xref>, <xref ref-type="bibr" rid="bib65">[65]</xref>, <xref ref-type="bibr" rid="bib66">[66]</xref>]. Previous work showed that the genetic ablation of nNOS results in cognitive deficit in mice, emphasizing the role of NO in learning and memory [<xref ref-type="bibr" rid="bib67">67</xref>]. Schizophrenic patients that were treated with NO donor nitroprusside, showed improvement of symptoms (attention, cognitive and working memory) (see <xref ref-type="table" rid="tbl2">Table 2</xref>) [<xref ref-type="bibr" rid="bib68">68</xref>,<xref ref-type="bibr" rid="bib69">69</xref>]. All these studies suggested that NO deficiency plays a role in the pathology of schizophrenia.</p>
</sec>
<sec id="sec5">
<label>5</label>
<title>Bipolar disorder (BPD)</title>
<p id="p0055">BPD is a chronic mental illness also referred to as manic depressive illness [<xref ref-type="bibr" rid="bib70">70</xref>]. Accurate and early diagnosis of BPD is difficult and more than 1% of individuals suffer from this kind of neuropathology globally [<xref ref-type="bibr" rid="bib71">71</xref>]. On the basis of severity and duration of the manic and depressive episodes, the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [<xref ref-type="bibr" rid="bib72">72</xref>] divide BPD into four categories, bipolar I disorder, bipolar II disorder, cyclothymia and residual category [<xref ref-type="bibr" rid="bib70">70</xref>]. It has been revealed in some studies that defects in dopaminergic and serotonergic pathways are responsible for the development of BPD [<xref ref-type="bibr" rid="bib70">70</xref>,<xref ref-type="bibr" rid="bib73">73</xref>]. The role of NO signalling in BPD has also been reported [<xref ref-type="bibr" rid="bib74">74</xref>]. NOS activity was reduced in blood platelets of patients suffering from BPD compared to healthy individuals [<xref ref-type="bibr" rid="bib75">75</xref>]. Another study has shown that lithium treatment increases the level of NO in plasma of patients suffering from this disease, indicating a role of lithium in regulation of NO signalling in subjects with this pathology during depressive episodes (see <xref ref-type="table" rid="tbl2">Table 2</xref>) [<xref ref-type="bibr" rid="bib76">76</xref>]. In this study, plasma NO level in bipolar depression was not different from healthy controls. Other works revealed that NO and nitrite level in plasma of bipolar patients was higher than in healthy controls (see <xref ref-type="fig" rid="fig4">Fig. 4</xref>) [<xref ref-type="bibr" rid="bib77">77</xref>]. A meta-analysis carried out by Andreazza et al. has confirmed an increased activity of the NO signalling in patients with BPD [<xref ref-type="bibr" rid="bib78">78</xref>]. The controversy of these data can be explained by the differences in the stage of the disease and medications used [<xref ref-type="bibr" rid="bib76">76</xref>]. Nevertheless, the accumulated data can show the involvement of NO in BPD, although its mechanistic role needs further investigation.</p>
</sec>
<sec id="sec6">
<label>6</label>
<title>Migraine</title>
<p id="p0060">Migraine is a reversible and chronic neurological disorder with severe or moderate headache. The major symptoms associated with migraine are cutaneous allodynia, phonophobia, photophobia, dizziness, vertigo and different gastrointestinal problems [<xref ref-type="bibr" rid="bib79">79</xref>]. According to WHO, migraine is the second most common disabling neurological disorder and the third most common medical condition of the world, in which 33% of women and 13% of men are suffering from it [<xref ref-type="bibr" rid="bib79">79</xref>,<xref ref-type="bibr" rid="bib80">80</xref>]. The role of NO in migraine was reported many years ago. Blood sample analysis of migraine patients revealed an increased level of cGMP, nitrite, neurokine A and calcitonin gene-related peptide (CGRP), which indicates the association of NO with migraine [<xref ref-type="bibr" rid="bib81">81</xref>,<xref ref-type="bibr" rid="bib82">82</xref>]. A variety of factors affect the formation and release of NO, such as bradykinin, NMDA, 5-hydroxytryptamine (5-HT<sub>2B/C</sub>) receptors, substance P, histamine, acetylcholine, and others [<xref ref-type="bibr" rid="bib83">[83]</xref>, <xref ref-type="bibr" rid="bib84">[84]</xref>, <xref ref-type="bibr" rid="bib85">[85]</xref>], which indicates its involvement in central pain sensation. Altogether, these data indicate the involvement of NO in the mechanisms of migraine and headache [<xref ref-type="bibr" rid="bib82">82</xref>,<xref ref-type="bibr" rid="bib86">86</xref>]. Glyceryl trinitrite (GTN), or sodium nitroprusside, was found to initiate headache and migraine symptoms in workers at explosive industry. This was the first direct evidence of the role of NO in migraine [<xref ref-type="bibr" rid="bib87">87</xref>]. Further studies of NO donor molecules, such as GTN and isosorbide dinitrate, on migraineurs (people who are suffering from migraine) and non-migraineurs showed that migraineurs are more sensitive to the NO donor compounds than non-migraineurs [<xref ref-type="bibr" rid="bib88">88</xref>,<xref ref-type="bibr" rid="bib89">89</xref>]. Nitrate and nitrite concentration in blood was higher in migraineurs compared to control patients (see <xref ref-type="fig" rid="fig4">Fig. 4</xref>). These results indicate that NO is involved in initiation and maintenance of pain in migraine [<xref ref-type="bibr" rid="bib90">90</xref>]. In animal models, headache feature was not investigated, but biochemical analysis has been done. Treatment with GTN in rats resulted in the increase of nNOS in trigeminal nerve ending, NO in cortical regions, and c-fos expression in trigeminal nucleus caudalis [<xref ref-type="bibr" rid="bib82">82</xref>,<xref ref-type="bibr" rid="bib91">91</xref>]. Along with this, reduced superoxide dismutase (SOD) expression and increased cortical blood flow were also found in animal models after GTN injections [<xref ref-type="bibr" rid="bib92">92</xref>,<xref ref-type="bibr" rid="bib93">93</xref>]. Treatment with cGMP-hydrolyzing phosphodiesterase 5 inhibitor, Sildenafil, led to increased migraine pain in migraineurs compared to controls [<xref ref-type="bibr" rid="bib94">94</xref>]. Histamine is reported to induce headache in migraineurs and use of a histamine antagonist, Mepyramine, reverted this effect (see <xref ref-type="table" rid="tbl2">Table 2</xref>) [<xref ref-type="bibr" rid="bib95">95</xref>,<xref ref-type="bibr" rid="bib96">96</xref>]. However, when the NOS-inhibitor L-NG-methylarginine hydrochloride (was administered to histamine-induced migraine patients, no significant changes were found [<xref ref-type="bibr" rid="bib97">97</xref>]. Nevertheless, in general, the published data indicate that NO signalling may play a role in the development of migraine.</p>
</sec>
<sec id="sec7">
<label>7</label>
<title>Epilepsy</title>
<p id="p0065">Epilepsy is the most common neurological disorder that affects approximately 50 million people worldwide [<xref ref-type="bibr" rid="bib98">98</xref>]. It is characterized mainly by recurrent seizures accompanied by loss of consciousness [<xref ref-type="bibr" rid="bib98">98</xref>]. Here we discuss the involvement of NO in epilepsy. NO regulates excitatory and inhibitory neurotransmission in both physiological and pathological conditions [<xref ref-type="bibr" rid="bib99">99</xref>]. There is some controversy over the role of NO signalling in the development of epilepsy. Previous reports indicated that NO plays a role of anticonvulsant while other showed that it leads to pro-convulsant effect [<xref ref-type="bibr" rid="bib99">99</xref>]. Thus, rats with epilepsy induced by NMDA injection were treated with methylene blue, known as a nNOS inhibitor. The methylene blue treatment increased the symptoms of epilepsy [<xref ref-type="bibr" rid="bib100">100</xref>]. It is worth mentioning that methylene blue appears to be a guanylate cyclase inhibitor that does not interfere with NOS [<xref ref-type="bibr" rid="bib101">101</xref>]. This casts doubt on the conclusion of the above-mentioned [<xref ref-type="bibr" rid="bib100">100</xref>] study. Nevertheless, when a precursor of NO <sc>l</sc>-arginine was given, it reduced the symptoms of epilepsy [<xref ref-type="bibr" rid="bib99">99</xref>,<xref ref-type="bibr" rid="bib102">102</xref>]. Also, in DL, homocysteine-thoiolactone (H)-induced seizure model, <sc>l</sc>-arginine provided protection and the NOS inhibitor N(G)-nitro-<sc>l</sc>-Arginine methyl ester (<sc>l</sc>-NAME) treatment potentiated the incidence of seizure (see <xref ref-type="table" rid="tbl2">Table 2</xref>) [<xref ref-type="bibr" rid="bib103">103</xref>]. The researchers concluded that NO is responsible for protection against epilepsy. However, in another study, increased level of NMDA subunit NR2B receptor in epileptic dysplastic human neocortex indicated the involvement of NO [<xref ref-type="bibr" rid="bib104">104</xref>] and overexpression of nNOS [<xref ref-type="bibr" rid="bib105">105</xref>] in the pathogenesis of epilepsy was found. In Pentylenetetrazol (PTZ)-induced epilepsy in rats, overexpression of NO and lipid peroxidation was reported in the brain and antioxidant treatment normalised the level of both (see <xref ref-type="fig" rid="fig4">Fig. 4</xref>) [<xref ref-type="bibr" rid="bib106">106</xref>].</p>
</sec>
<sec id="sec8">
<label>8</label>
<title>Addiction</title>
<p id="p0070">Addiction is a brain disorder distinguished by compulsive engagement in rewarding stimuli. To test the involvement of NO in addiction, morphine addict rats were treated with NOS inhibitors, <sc>l</sc>-NAME and nitro-<sc>l</sc>-arginine (L-NNA) and tested the drug withdrawal symptoms. The rats showed reduced morphine withdrawal symptoms and when treated with NO donor compound, isosorbide nitrate, relapse of withdrawal symptoms were detected [<xref ref-type="bibr" rid="bib108">108</xref>,<xref ref-type="bibr" rid="bib109">109</xref>]. Immunohistochemical studies in morphine-dependent mice showed increased number of nNOS positive cells in olfactory bulb, cerebellum, medulla oblongata, and locus coeruleus and reduction in the hypothalamus. When treated with an opioid receptor antagonist naloxone, increased nNOS immunoreactivity was found in hypothalamus [<xref ref-type="bibr" rid="bib110">110</xref>]. These results can explain the role of NO in opioid dependence and withdrawal symptoms [<xref ref-type="bibr" rid="bib110">110</xref>]. Cocaine is also responsible for induction of nNOS activity in hippocampus of rat brain [<xref ref-type="bibr" rid="bib111">111</xref>] and tempol treatment, an antioxidant agent, abolished cocaine psychomotor sensitization and condition reward via reduction in oxidative stress [<xref ref-type="bibr" rid="bib112">112</xref>]. Studies on alcohol addiction showed that ethanol reduces the NO synthesis in peripheral system and also the level of NO in exhaled breath (see <xref ref-type="fig" rid="fig4">Fig. 4</xref>) [<xref ref-type="bibr" rid="bib113">113</xref>]. When <sc>l</sc>-NAME (an inhibitor of NO) was given to rats, it led to increase in ethanol-induced narcosis; and when isosobarbide dinitrate (an NO donor) was applied, the effect of necrosis was reduced in rats [<xref ref-type="bibr" rid="bib114">114</xref>]. Further, treatment with 7-nitroindazole(7-NI) (an inhibitor of nNOS) enhances hypnotic effect of ethanol in animals (see <xref ref-type="table" rid="tbl2">Table 2</xref>) [<xref ref-type="bibr" rid="bib115">115</xref>]. Following the mentioned evidence, we suggest that NO signalling plays an important role in addiction.</p>
</sec>
<sec id="sec9">
<label>9</label>
<title>Alzheimer's disease (AD)</title>
<p id="p0075">Alzheimer's disease (AD) is the most common chronic neurodegenerative disorder [<xref ref-type="bibr" rid="bib116">116</xref>]. Aging is the main causative factor for the development of AD and memory loss [<xref ref-type="bibr" rid="bib116">116</xref>]. Cognitive deficits and language impairment are major symptoms of AD [<xref ref-type="bibr" rid="bib117">117</xref>,<xref ref-type="bibr" rid="bib118">118</xref>]. Senile plaques and neurofibrillary tangles are the main pathological hallmarks of AD [<xref ref-type="bibr" rid="bib117">117</xref>]. Tannenbaum and co-workers have tested the involvement of SNO in AD using SNO trapping by TriAryl Phosphine (SNOTRAP) method in conjunction with mass spectrometry [<xref ref-type="bibr" rid="bib119">119</xref>]. They used the CK-p25-inducible mouse model of AD, and a total of 251 SNO-proteins were detected in the AD model. Among them, 135 SNO proteins were found exclusively for early neurodegeneration in cortex [<xref ref-type="bibr" rid="bib119">119</xref>]. These proteins found are known to be associated with metabolism, synaptic function and AD progression [<xref ref-type="bibr" rid="bib119">119</xref>]. According to the GO analysis of CK-p25 mouse model of AD, increased number of SNO proteins were found in cortex and hippocampus compared to control mice. Increased level of amyloid β protein, DNA damage, neuroinflammation and behavioral abnormalities were observed in CK-p25 mice. An increase in GSNO was found in hippocampus and cortex but not in cerebellum of 2-week-old CK-p25 mice. SNO level of PSD95 was also detected in these mice. SNO proteins associated with AD, such as glutamate ionotrophic receptor NMDA 2B (Grin2b), microtubule associated protein (MAPT), glycogen synthase kinase 3β(Gsk3b), lipoprotein receptor-related (LRP), NADH, ubiquinone oxidoreductase core subunit S1 (Ndufs1), cytochrome <italic>c</italic> oxidase subunit 6B1(Cox6b1) and GAPDH were detected in cortex of Ck-p25 mice brain. Elevated phosphorylation of GSK3β and tau (Mapt) was found in the transgenic mice. It has been shown that these proteins are involved in neuronal cell death in AD [<xref ref-type="bibr" rid="bib120">120</xref>]. PKCε and PKCγ, isoforms of PKC were found to be SNOed in CK-p25 mice brain. Lipoprotein receptor-related protein (LRP) gene is associated with progression of AD [<xref ref-type="bibr" rid="bib119">119</xref>,<xref ref-type="bibr" rid="bib121">121</xref>]. Researchers suggested that SNO-LRP and SNO-PKC in CK-p25 mice disturbed amyloid β processing and clearance, which further lead to amyloid plaque deposition [<xref ref-type="bibr" rid="bib119">119</xref>]. Amal et al. used P301S mouse model of tauopathy to test the involvement of SNO in the pathology [<xref ref-type="bibr" rid="bib122">122</xref>]. This work revealed reprogramming of the S-nitroso-proteome in the mutant compared to the control group in both cortex and hippocampus of 2-month-old mice. Increased level of 3-nirotyrosine in the CA1 and entorhinal cortex regions of P301S mice was found. This indicates nitrosative and oxidative stress in the brain of the mutant. This study revealed the role of the noncanonical Wnt/Ca<sup>2+</sup> (NC-WCa) signalling in the cortex of P301S mice and found an elevated level of phosphorylated CaMKII. Ring Finger Protein 213 (RNF213), an E3 ubiquitin ligase, was S-nitrosylated, and led to an increase in the level of nuclear factor of activated T-cells 1 (NFAT-1) and FILAMIN-A, which resulted in the potentiation of the NC-WCa signalling [<xref ref-type="bibr" rid="bib122">122</xref>].</p>
<p id="p0080">Cyclin dependent kinase (Cdk5) is a serine/threonine kinase enzyme which has diverse functions in the development of brain, synaptic plasticity, regulation of neuronal migration and differentiation [<xref ref-type="bibr" rid="bib123">123</xref>]. Dysregulation/dysfunction or modification of Cdk5 leads to the development of many neurological disorders [<xref ref-type="bibr" rid="bib123">123</xref>]. In neuronal cells, Cdk5 scaffolds with the nNOS/PSD95/NMDAR complex which are embedded in the membrane. Cdk5 is S-nitrosylated by interacting with nNOS complex under pathological conditions [<xref ref-type="bibr" rid="bib124">124</xref>,<xref ref-type="bibr" rid="bib125">125</xref>]. Post-mortem studies revealed the presence of high level of SNO-Cdk5 protein in the AD brain compared to the normal brain [<xref ref-type="bibr" rid="bib126">126</xref>]. S-nitrosylation of Cdk5 at Cys-83 and Cys-157 residues activate the function of Cdk5 (see <xref ref-type="table" rid="tbl1">Table 1</xref>) [<xref ref-type="bibr" rid="bib124">124</xref>,<xref ref-type="bibr" rid="bib125">125</xref>]. Activation of Cdk5 leads to phosphorylation of its substrate ataxia telangiectasia mutated kinase (ATM), which is a proapoptotic protein kinase. In cultured cortical neurons, SNO-Cdk5 is found to enhance the amyloid β (Aβ)-induced synaptic degeneration [<xref ref-type="bibr" rid="bib126">126</xref>]. Cdk5 mutant protein or treatment with NOS inhibitor, N-nitro-<sc>l</sc>-arginine (NNA), in the cellular system provided protection against apoptosis (see <xref ref-type="table" rid="tbl2">Table 2</xref>) [<xref ref-type="bibr" rid="bib126">126</xref>]. In summary, aberrant SNO of Cdk5 is responsible for Aβ-induced synaptic degeneration (see <xref ref-type="fig" rid="fig3">Fig. 3</xref>) [<xref ref-type="bibr" rid="bib126">126</xref>]. Importantly, NMDAR plays a role in Aβ-induced synaptic loss [<xref ref-type="bibr" rid="bib127">127</xref>,<xref ref-type="bibr" rid="bib128">128</xref>]. Cdk5 activates NMDAR via phosphorylation and <italic>p</italic>-NMDAR activates nNOS in ischemic insult [<xref ref-type="bibr" rid="bib129">129</xref>]. The resulting SNO-Cdk5 transnitrosylates Drp-1 protein, a GTPase protein that regulates mitochondrial dynamics such as mitochondrial fission and fusion in cells, with detrimental effects. For example, treatment of the primary cortical neurons with Aβ led to SNO of Drp-1 at Cys-644 residue, which resulted in enhanced mitochondrial fission, impairment of energy homeostasis and dendritic spine loss (see <xref ref-type="table" rid="tbl1">Table 1</xref>) [<xref ref-type="bibr" rid="bib130">130</xref>]. A mutant of Drp-1 (C644A) protected the cells from Aβ-induced synaptic loss [<xref ref-type="bibr" rid="bib130">130</xref>]. Post mortem studies have confirmed the presence of SNO-Drp-1 in the brain of AD patients and peripheral blood lymphocytes but not in controls [<xref ref-type="bibr" rid="bib131">131</xref>,<xref ref-type="bibr" rid="bib132">132</xref>]. The researchers concluded that S-nitrosylation of Drp-1 plays a major role in AD progression (see <xref ref-type="fig" rid="fig3">Fig. 3</xref>) [<xref ref-type="bibr" rid="bib131">131</xref>,<xref ref-type="bibr" rid="bib132">132</xref>].</p>
<p id="p0085">Protein disulphide isomerase (PDI) is a chaperon protein, located in endoplasmic reticulum (ER) and plays a major role in protein processing and folding. SNO-PDI was found in post-mortem AD brain [<xref ref-type="bibr" rid="bib133">133</xref>]. PDI was S-nitrosylated in its active site and inhibited its activity, which led to accumulation of unfolded proteins (see <xref ref-type="fig" rid="fig3">Fig. 3</xref>) [<xref ref-type="bibr" rid="bib133">133</xref>]. Furthermore, a zinc metalloprotease insulin degrading enzyme (IDE) was found to be S-nitrosylated at multiple sites (Cys819, Cys789, Cys966, Cys178) in the presence of GSNO (see <xref ref-type="table" rid="tbl1">Table 1</xref>). S-nitrosylation of IDE was found to be involved in the pathogenesis of AD [<xref ref-type="bibr" rid="bib134">134</xref>]. Mutation in Apo lipoprotein E (ApoE) was reported in late onset of AD [<xref ref-type="bibr" rid="bib135">135</xref>]. ApoE appears to be S-nitrosylated in patients with AD, and recent studies have reported hippocampal SNOs of ApoE2 and ApoE3. These studies suggest that SNO of ApoE proteins may play a role in AD development by inhibiting lipid homeostasis (see <xref ref-type="table" rid="tbl1">Table 1</xref>) [<xref ref-type="bibr" rid="bib136">136</xref>]. SNO-GAPDH has also found to be S-nitrosylated in various brain regions including cortex, substantia nigra, and hippocampus in postmortem AD brain compared to control brains [<xref ref-type="bibr" rid="bib137">137</xref>], which suggested the involvement of SNO-GAPDH in AD [<xref ref-type="bibr" rid="bib137">137</xref>].</p>
<p id="p0090">Thus, SNO plays a crucial role in the pathogenesis of AD, affecting the activity of numerous proteins. We believe that unravelling the SNO-related signalling pathways will pave the way to new effective therapies against the development of AD.</p>
</sec>
<sec id="sec10">
<label>10</label>
<title>Parkinson's disease (PD)</title>
<p id="p0095">Parkinson's disease (PD) is the second most common disease after AD in elderly people [<xref ref-type="bibr" rid="bib138">138</xref>]. It is characterized by four major cardinal features: bradykinesia, rigidity, postural instability and resting tremor [<xref ref-type="bibr" rid="bib139">139</xref>]. In PD, NO plays both a neuroprotective and neuro-destructive role and was reported in rodent models and human cases of PD [<xref ref-type="bibr" rid="bib9">9</xref>,<xref ref-type="bibr" rid="bib140">140</xref>,<xref ref-type="bibr" rid="bib141">141</xref>]. S-nitrosylation of many proteins was found to be involved in PD progression [<xref ref-type="bibr" rid="bib9">9</xref>]. Biochemical analysis of postmortem PD brains revealed increase in oxidative/nitrosative stress, which plays a major role in PD pathogenesis [<xref ref-type="bibr" rid="bib142">142</xref>]. NO forms peroxynitrite in the presence of hydrogen peroxide [<xref ref-type="bibr" rid="bib143">143</xref>]. Production of peroxynitrite leads to the modification of α-synuclein protein by di-tyrosine synthesis, which further stabilizes the filamentous structure of α-synuclein resulting in aggregate formation [<xref ref-type="bibr" rid="bib144">144</xref>]. Analysis of postmortem PD brains in substantia nigra and cortical regions showed increased level of nitrated α-synuclein [<xref ref-type="bibr" rid="bib145">145</xref>]. Nitrated α-synuclein was also found in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mice model of PD [<xref ref-type="bibr" rid="bib146">146</xref>]. S-nitrosylation of different proteins, such parkin [<xref ref-type="bibr" rid="bib147">147</xref>], DJ-1 [<xref ref-type="bibr" rid="bib148">148</xref>], PDI [<xref ref-type="bibr" rid="bib133">133</xref>,<xref ref-type="bibr" rid="bib149">149</xref>], X-linked inhibitor of apoptosis (XIAP) [<xref ref-type="bibr" rid="bib150">150</xref>] and Prx2 [<xref ref-type="bibr" rid="bib151">151</xref>] were found to be associated with PD (see <xref ref-type="table" rid="tbl1">Table 1</xref>). Previous works have shown that nitrosative stress led to S-nitrosylation of parkin, causing inhibition of its ubiquitination activity, which lead to the formation of Lewy bodies and PD progression. These changes were found both in rodents and in human postmortem PD brain [<xref ref-type="bibr" rid="bib147">147</xref>,<xref ref-type="bibr" rid="bib152">152</xref>]. Further, human studies confirmed the SNO modification of parkin in PD pathogenesis [<xref ref-type="bibr" rid="bib147">147</xref>,<xref ref-type="bibr" rid="bib152">152</xref>,<xref ref-type="bibr" rid="bib153">153</xref>] as well as in different mouse models of PD [<xref ref-type="bibr" rid="bib140">140</xref>,<xref ref-type="bibr" rid="bib152">152</xref>].</p>
<p id="p0100">PDI is a chaperone protein residing inside the endoplasmic reticulum and contributing to protein folding and disulfide formation by its isomerase activity [<xref ref-type="bibr" rid="bib154">154</xref>]. Researchers found that S-nitrosylation of PDI inhibits its activity [<xref ref-type="bibr" rid="bib133">133</xref>]. They have showed that toxicant rotenone increases the S-nitrosylation of PDI in SH-SY-5Y cell lines [<xref ref-type="bibr" rid="bib133">133</xref>]. Further, SNO-PDI was also found in the brain of postmortem PD patients, which may emphasize its involvement in the pathology [<xref ref-type="bibr" rid="bib133">133</xref>,<xref ref-type="bibr" rid="bib155">155</xref>].</p>
<p id="p0105">XIAP is an E3 ubiquitin ligase protein which participates in ubiquitination and degradation of caspase 3,7,9 and promotes cell survival [<xref ref-type="bibr" rid="bib156">156</xref>]. High level of NO leads to SNO modification of XIAP and inhibition of its ubiquitination activity. In rotenone-treated HEK-293 and N2a cell line models of PD, S-nitrosylation of -XIAP is well reported (see <xref ref-type="table" rid="tbl1">Table 1</xref>) [<xref ref-type="bibr" rid="bib150">150</xref>]. Human studies on PD patient's postmortem brain also confirm the SNO modification of XIAP [<xref ref-type="bibr" rid="bib150">150</xref>,<xref ref-type="bibr" rid="bib157">157</xref>].</p>
<p id="p0110">Prx2 has antioxidant properties since it catalyzes the removal of peroxides from cells, and its level is upregulated when oxidative stress is increased in the cells [<xref ref-type="bibr" rid="bib158">158</xref>]. S-nitrosylation of Prx2 at Cys-51 and Cys-172 inhibited its antioxidant activity [<xref ref-type="bibr" rid="bib151">151</xref>], which leads to increase of oxidative stress. Importantly, increased level of SNO-Prx2 is reported in PD human postmortem samples and PD animal models (see <xref ref-type="table" rid="tbl1">Table 1</xref>) [<xref ref-type="bibr" rid="bib151">151</xref>].</p>
<p id="p0115">PD toxicant rodent models, such as MPTP, 6-hydroxydopamine (6-OHDA), lipopolysaccharides (LPS), manganese ethylene bis-dithiocarbamate (maneb) and 1,1′-dimethyl-4,4-bipyridinium dichloride (paraquat), found to have high expression levels of iNOS, nNOS and NO in the brain (see <xref ref-type="fig" rid="fig4">Fig. 4</xref>) [<xref ref-type="bibr" rid="bib159">[159]</xref>, <xref ref-type="bibr" rid="bib160">[160]</xref>, <xref ref-type="bibr" rid="bib161">[161]</xref>, <xref ref-type="bibr" rid="bib162">[162]</xref>]. iNOS-KO mouse model showed resistance to MPTP-induced cell death [<xref ref-type="bibr" rid="bib163">163</xref>]. Furthermore, NOS inhibitors, 7-nitroindazole and monoamine B oxidase (MAO-B) inhibitor pargyline, protected cell death of dopaminergic neurons in mouse model of PD induced by MPTP(see <xref ref-type="table" rid="tbl2">Table 2</xref>) [<xref ref-type="bibr" rid="bib164">164</xref>]. Together, these studies conclude that NO is involved in MPTP-mediated neurodegeneration. 6-OHDA, is another toxicant used to induce PD in rat, which its intoxication leads to the increased level of iNOS and NO in the rat brain. Pretreatment of animals with NOS inhibitor <sc>l</sc>-NAME protects from dopaminergic cell death in substantia nigra pars compacta (SNPc) and from dopamine depletion in striatum [<xref ref-type="bibr" rid="bib165">165</xref>,<xref ref-type="bibr" rid="bib166">166</xref>]. Intranigral injection of 6-OHDA caused activation of microglial cells, cytokine production, generation of free radicals and increase of NO production, which ultimately led to the death of dopaminergic neurons in PD [<xref ref-type="bibr" rid="bib160">160</xref>]. GW274150, an iNOS inhibitor, reduced microglial activation, cytokine, ROS and NO production, and provided neuroprotection against the 6-OHDA-induced rodent model of PD (see <xref ref-type="table" rid="tbl2">Table 2</xref>) [<xref ref-type="bibr" rid="bib167">167</xref>]. Rotenone, used as a toxicant to induce PD in rodents, inhibited mitochondrial complex 1 and induced oxidative stress [<xref ref-type="bibr" rid="bib168">168</xref>]. Furthermore, it reduced the level of glutathione, which further leads to the increase in nitrite levels and apoptosis [<xref ref-type="bibr" rid="bib169">169</xref>]. Rotenone enhanced NOS enzymatic activity, increased 3-nitrotyrosine (3NT) level, reduced dopamine content and promoted the degeneration of dopaminergic cells [<xref ref-type="bibr" rid="bib170">170</xref>]. Treatment with the NOS inhibitor 7-NI reduced NOS activity and 3-NT level and provided protection against rotenone-induced toxicity (see <xref ref-type="table" rid="tbl2">Table 2</xref>) [<xref ref-type="bibr" rid="bib170">170</xref>]. Rotenone can induce nitrosative stress by disrupting the redox activity of PDI [<xref ref-type="bibr" rid="bib171">171</xref>]. In rat striatal synaptosomes treated with methamphetamine, which is also used to produce a toxic model of PD, activated alpha(7) nicotinic receptors and increased the level of intrasynaptosomal calcium, NOS and PKC [<xref ref-type="bibr" rid="bib172">172</xref>]. All this led to cell death of dopaminergic neurons in the PD rat model [<xref ref-type="bibr" rid="bib172">172</xref>]. The above data unequivocally point to the involvement of NO and nitrosative stress in the pathogenesis of PD.</p>
</sec>
<sec id="sec11">
<label>11</label>
<title>Huntington disease (HD)</title>
<p id="p0120">Huntington disease (HD) is a dominantly inherited autosomal neurodegenerative disorder [<xref ref-type="bibr" rid="bib173">173</xref>]. The main features of HD are motor dysfunction, cognitive impairment and psychiatric disturbances [<xref ref-type="bibr" rid="bib174">174</xref>]. The main cause of this disease is expansion of CAG repeats in Huntingtin (HTT) protein on chromosome number 4 [<xref ref-type="bibr" rid="bib173">173</xref>]. The expansion of CAG repeats in Mutant HTT (mHTT) protein results in the formation of long polyglutamine (polyQ) repeats making mHTT a toxic protein. This causes dysfunction of normal homeostasis and cell death of the neurons [<xref ref-type="bibr" rid="bib175">175</xref>]. The disease starts from the striatum, and when it progresses, it reaches the cortex [<xref ref-type="bibr" rid="bib173">173</xref>]. Although not enough information is available on the involvement of NO in HD, it is known that the key proteins involved in the progression of HD also become S-nitrosylated. In R6/1 mutant HD mouse, the level of expression and biochemical activity of nNOS was found to be reduced in the striatum and cerebellum (see <xref ref-type="fig" rid="fig4">Fig. 4</xref>). Along with this, behavioral abnormalities were also reported in R6/1 HD mice [<xref ref-type="bibr" rid="bib176">176</xref>]. In another study on SK-N-SH human neuroblastoma cell lines, knockdown of nNOS appeared to be protective for the cells. This can be explained by the fact that inhibition of nNOS may induce autophagy [<xref ref-type="bibr" rid="bib177">177</xref>]. Mitochondrial dysfunction is the major cause of the development of neurodegenerative disorders. In this context, SNO of dynamin-related protein (Drp-1), the activator of mitochondrial fission, was found to be increased in the human postmortem HD brain and striatum of the transgenic HD mouse model [<xref ref-type="bibr" rid="bib178">178</xref>]. Further investigation reported that SNO-Drp-1 disrupts the mitochondrial dynamics eventually leading to cell death [<xref ref-type="bibr" rid="bib179">179</xref>]. Another study has revealed that PTM of HTT protein in N-548 fragment is implicated in the expansion of polyQ repeats. Overexpression of NOS is responsible for SNO of normal HTT protein (see <xref ref-type="table" rid="tbl1">Table 1</xref>) [<xref ref-type="bibr" rid="bib174">174</xref>]. Investigation of the human HD patients indicate that abnormal NO signalling in the peripheral blood tissues is also responsible for the disease progression [<xref ref-type="bibr" rid="bib178">178</xref>].</p>
</sec>
<sec id="sec12">
<label>12</label>
<title>Amyotrophic Lateral Sclerosis (ALS)</title>
<p id="p0125">Amyotrophic Lateral Sclerosis (ALS) is an idiopathic neurodegenerative disorder [<xref ref-type="bibr" rid="bib180">180</xref>]. It is also known as Motor Neuron Disease. This disease is mainly characterized with permanent impairment of lower and upper motor neurons [<xref ref-type="bibr" rid="bib181">181</xref>]. ALS is sporadic in nature in 85–90% of cases but genetic factors (10–15%) also contribute in the development of this disease. ALS is more common in men than in women [<xref ref-type="bibr" rid="bib182">182</xref>]. Until now, approximately 30 genes responsible for the development of ALS pathogenesis have been detected [<xref ref-type="bibr" rid="bib181">181</xref>]. Toxic gain of function due to mutations in SOD1 is one of the major culprits in ALS [<xref ref-type="bibr" rid="bib180">180</xref>]. Mutant SOD1 <sup>G93A</sup> is responsible for SNO of GAPDH, which enhances the nuclear translocation of GAPDH-Siah complex in NSC34 motor neurons, which further enhances apoptotic cell death. When deprenyl, a selective inhibitor of Type B monoamine oxidase, was added, it inhibited the SNO of GAPDH and provided protection against apoptosis (see <xref ref-type="table" rid="tbl2">Table 2</xref>). This study concludes that mutations of SOD induce SNO of GAPDH, which plays a role in the neuronal apoptosis in ALS model [<xref ref-type="bibr" rid="bib183">183</xref>]. In contrast, it has been found that mutations of SOD1 increase its denytrosylation activity, and denytrosylation of many mitochondrial proteins can hamper the normal homeostasis in mitochondria, ultimately leading to cell death in ALS models, whilst addition of SNO-donor compounds to the mutant SOD1-containing cells prevents this course of events [<xref ref-type="bibr" rid="bib184">184</xref>]. This study implies that denytrosylation is important for the cell survival. This conclusion was confirmed by another study, where lymphocyte cells of ALS patients were treated with the NO-releasing agent diethyl NONOate. In this work, the cell death ratio was found to be lower in the diethyl NONOate-treated lymphocytes of ALS patients compared to controls [<xref ref-type="bibr" rid="bib185">185</xref>].</p>
<p id="p0130">The role of PDI in the development of ALS is well established. The level of PDI is increased in spinal cord and CSF of ALS patients [<xref ref-type="bibr" rid="bib186">186</xref>] and spinal cord of SOD1 <sup>G93A</sup> transgenic rat [<xref ref-type="bibr" rid="bib187">187</xref>] and mice [<xref ref-type="bibr" rid="bib188">188</xref>] models of ALS. SNO of PDI in the spinal cord of ALS patients and SOD1 <sup>G93A</sup> transgenic mice was found to be responsible for the disease progression. Pharmacological agents that mimic the active site of PDI provide protection to SOD1 <sup>G93A</sup> transgenic mice [<xref ref-type="bibr" rid="bib155">155</xref>]. Tyrosine nitration of PDI and ERp57 protein has also been reported in SOD1 <sup>G93A</sup> transgenic mice [<xref ref-type="bibr" rid="bib189">189</xref>,<xref ref-type="bibr" rid="bib190">190</xref>]. Treatment with NOS inhibitor, N-nitro-<sc>l</sc>-Arginine, inhibited both SNO of PDI and the mutant aggregate formation induced by SOD1(see <xref ref-type="table" rid="tbl2">Table 2</xref>) [<xref ref-type="bibr" rid="bib191">191</xref>].</p>
</sec>
<sec id="sec13">
<label>13</label>
<title>Multiple sclerosis (MS)</title>
<p id="p0135">MS is a chronic neurological disorder in which myelinated exons of CNS started to degenerate by inflammation and autoimmune defects [<xref ref-type="bibr" rid="bib192">192</xref>]. Epidemiological studies reveal that around 2.3 million people are suffering from this disease worldwide [<xref ref-type="bibr" rid="bib193">193</xref>]. Environmental and genetic factors are responsible for the development of MS [<xref ref-type="bibr" rid="bib194">194</xref>]. Role of NO in MS has been established but it is controversial in some cases [<xref ref-type="bibr" rid="bib195">195</xref>]. Genetic studies have found the association between iNOS gene mutation and MS progression [<xref ref-type="bibr" rid="bib196">196</xref>]. High level of iNOS RNA is found in the CNS of MS patients and animal models of MS [<xref ref-type="bibr" rid="bib197">197</xref>]. Further, iNOS immunoreactivity has also been found in active lesions of MS patients compared to the normal human brain [<xref ref-type="bibr" rid="bib198">198</xref>]. NO metabolites (nitrate and nitrite) level was increased in the CSF, urine and plasma of MS patients (see <xref ref-type="fig" rid="fig4">Fig. 4</xref>) [<xref ref-type="bibr" rid="bib199">[199]</xref>, <xref ref-type="bibr" rid="bib200">[200]</xref>, <xref ref-type="bibr" rid="bib201">[201]</xref>]. These studies indicate that nitrite and nitrate can be used as potent markers for detection of MS. In some studies, nitrotyrosine has also been detected in MS patients [<xref ref-type="bibr" rid="bib202">202</xref>,<xref ref-type="bibr" rid="bib203">203</xref>]. Proteolipid protein (PLP) is responsible for maintenance and integrity of myelin sheath. Researchers hypothesized that S-nitrosylation of PLP (SNO-PLP) results in conformational and functional alterations of the protein, which lead to the disease progression (see <xref ref-type="table" rid="tbl1">Table 1</xref>) [<xref ref-type="bibr" rid="bib195">195</xref>,<xref ref-type="bibr" rid="bib204">204</xref>].</p>
</sec>
<sec id="sec14">
<label>14</label>
<title>Conclusions</title>
<p id="p0140">NO is one of the most important signalling molecules in the brain. It can play both protective/constitutive and destructive/toxic role, depending upon its regulation/production and interaction with different molecules in the cell. Therefore, NO is also referred to as a “double-edged sword”. A large body of the accumulated evidence suggests that NO is one of the key factors in the genesis of many brain-related disorders. Along with SNO, which targets a wide range of prominent intracellular proteins leading to alteration in signalling pathways, which may converge onto synaptic, neuronal and behavioral deficits. Although NO promotes neurogenesis, aberrant SNO may be responsible for different neurodevelopmental disorders, such as ASD. The SHANK3 study on NO implies it as an important pathological molecule in ASD. As neurons are probably the most vulnerable cell type in the body, oxidative and nitrosative stress and aberrant SNO play a role in the development of a variety of neuroinflammatory and neurodegenerative disorders, including PD, AD, HD, ALS and MS. Further, dysregulation of NO signalling can induce the development of different neuropsychiatric and neurological disorders, such as BPD, migraine, epilepsy, schizophrenia and addiction. Finally, pharmacological agents that can inhibit or augment the production of NO as well as new approaches to pharmacologically modulate formation of SNO-proteins can serve as a potential and promising approach for the treatment of diverse brain disorders.</p>
</sec>
<sec sec-type="COI-statement">
<title>Declaration of competing interest</title>
<p id="p0145">The authors have no competing interests to declare.</p>
</sec>
</body>
<back>
<ref-list id="cebib0010">
<title>References</title>
<ref id="bib1">
<label>1</label>
<element-citation id="sref1" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bredt</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Nitric oxide: a physiologic messenger molecule</article-title>
<source/>Annu. Rev. Biochem.
          <volume>63</volume>
<year>1994</year>
<fpage>175</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="pmid">7526779</pub-id>
</element-citation>
</ref>
<ref id="bib2">
<label>2</label>
<element-citation id="sref2" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bredt</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>P.M.</given-names>
</name>
</person-group>
<article-title>Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase</article-title>
<source/>Nature
          <volume>351</volume>
<issue>6329</issue>
<year>1991</year>
<fpage>714</fpage>
<pub-id pub-id-type="pmid">1712077</pub-id>
</element-citation>
</ref>
<ref id="bib3">
<label>3</label>
<element-citation id="sref3" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantu-Medellin</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Effects of T- and R-state stabilization on deoxyhemoglobin-nitrite reactions and stimulation of nitric oxide signaling</article-title>
<source/>Nitric Oxide : Biol. Chem.
          <volume>25</volume>
<issue>2</issue>
<year>2011</year>
<fpage>59</fpage>
<lpage>69</lpage>
</element-citation>
</ref>
<ref id="bib4">
<label>4</label>
<element-citation id="sref4" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Förstermann</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Isoforms of nitric oxide synthase characterization and purification from different cell types</article-title>
<source/>Biochem. Pharmacol.
          <volume>42</volume>
<issue>10</issue>
<year>1991</year>
<fpage>1849</fpage>
<lpage>1857</lpage>
<pub-id pub-id-type="pmid">1720618</pub-id>
</element-citation>
</ref>
<ref id="bib5">
<label>5</label>
<element-citation id="sref5" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muller</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Bicker</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Calcium-activated release of nitric oxide and cellular distribution of nitric oxide-synthesizing neurons in the nervous system of the locust</article-title>
<source/>J. Neurosci.
          <volume>14</volume>
<issue>12</issue>
<year>1994</year>
<fpage>7521</fpage>
<lpage>7528</lpage>
<pub-id pub-id-type="pmid">7527844</pub-id>
</element-citation>
</ref>
<ref id="bib6">
<label>6</label>
<element-citation id="sref6" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez-Collazo</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Requirement of nitric oxide and calcium mobilization for the induction of apoptosis in adrenal vascular endothelial cells</article-title>
<source/>FEBS Lett.
          <volume>413</volume>
<issue>1</issue>
<year>1997</year>
<fpage>124</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="pmid">9287129</pub-id>
</element-citation>
</ref>
<ref id="bib7">
<label>7</label>
<element-citation id="sref7" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brenman</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains</article-title>
<source/>Cell
          <volume>84</volume>
<issue>5</issue>
<year>1996</year>
<fpage>757</fpage>
<lpage>767</lpage>
<pub-id pub-id-type="pmid">8625413</pub-id>
</element-citation>
</ref>
<ref id="bib8">
<label>8</label>
<element-citation id="sref8" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chachlaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Garthwaite</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Prevot</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>The gentle art of saying NO: how nitric oxide gets things done in the hypothalamus</article-title>
<source/>Nat. Rev. Endocrinol.
          <volume>13</volume>
<issue>9</issue>
<year>2017</year>
<fpage>521</fpage>
<lpage>535</lpage>
<pub-id pub-id-type="pmid">28621341</pub-id>
</element-citation>
</ref>
<ref id="bib9">
<label>9</label>
<element-citation id="sref9" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamura</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases</article-title>
<source/>Neurobiol. Dis.
          <volume>84</volume>
<year>2015</year>
<fpage>99</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="pmid">25796565</pub-id>
</element-citation>
</ref>
<ref id="bib10">
<label>10</label>
<element-citation id="sref10" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deckel</surname>
<given-names>A.W.</given-names>
</name>
</person-group>
<article-title>Nitric oxide and nitric oxide synthase in Huntington's disease</article-title>
<source/>J. Neurosci. Res.
          <volume>64</volume>
<issue>2</issue>
<year>2001</year>
<fpage>99</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="pmid">11288139</pub-id>
</element-citation>
</ref>
<ref id="bib11">
<label>11</label>
<element-citation id="sref11" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaffrey</surname>
<given-names>S.R.</given-names>
</name>
</person-group>
<article-title>Protein S-nitrosylation: a physiological signal for neuronal nitric oxide</article-title>
<source/>Nat. Cell Biol.
          <volume>3</volume>
<issue>2</issue>
<year>2001</year>
<fpage>193</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="pmid">11175752</pub-id>
</element-citation>
</ref>
<ref id="bib12">
<label>12</label>
<element-citation id="sref12" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Marletta</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Mechanisms of S-nitrosothiol formation and selectivity in nitric oxide signaling</article-title>
<source/>Curr. Opin. Chem. Biol.
          <volume>16</volume>
<issue>5–6</issue>
<year>2012</year>
<fpage>498</fpage>
<lpage>506</lpage>
<pub-id pub-id-type="pmid">23127359</pub-id>
</element-citation>
</ref>
<ref id="bib13">
<label>13</label>
<element-citation id="sref13" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stamler</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Lamas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>F.C.</given-names>
</name>
</person-group>
<article-title>Nitrosylation: the prototypic redox-based signaling mechanism</article-title>
<source/>Cell
          <volume>106</volume>
<issue>6</issue>
<year>2001</year>
<fpage>675</fpage>
<lpage>683</lpage>
<pub-id pub-id-type="pmid">11572774</pub-id>
</element-citation>
</ref>
<ref id="bib14">
<label>14</label>
<element-citation id="sref14" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stamler</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds</article-title>
<source/>Proc. Natl. Acad. Sci. Unit. States Am.
          <volume>89</volume>
<issue>1</issue>
<year>1992</year>
<fpage>444</fpage>
<lpage>448</lpage>
</element-citation>
</ref>
<ref id="bib15">
<label>15</label>
<element-citation id="sref15" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Marletta</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Mechanisms of S-nitrosothiol formation and selectivity in nitric oxide signaling</article-title>
<source/>Curr. Opin. Chem. Biol.
          <volume>16</volume>
<issue>5</issue>
<year>2012</year>
<fpage>498</fpage>
<lpage>506</lpage>
<pub-id pub-id-type="pmid">23127359</pub-id>
</element-citation>
</ref>
<ref id="bib16">
<label>16</label>
<element-citation id="sref16" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hess</surname>
<given-names>D.T.</given-names>
</name>
</person-group>
<article-title>Protein S-nitrosylation: purview and parameters</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <volume>6</volume>
<issue>2</issue>
<year>2005</year>
<fpage>150</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="pmid">15688001</pub-id>
</element-citation>
</ref>
<ref id="bib17">
<label>17</label>
<element-citation id="sref17" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doulias</surname>
<given-names>P.T.</given-names>
</name>
</person-group>
<article-title>Structural profiling of endogenous S-nitrosocysteine residues reveals unique features that accommodate diverse mechanisms for protein S-nitrosylation</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>107</volume>
<issue>39</issue>
<year>2010</year>
<fpage>16958</fpage>
<lpage>16963</lpage>
<pub-id pub-id-type="pmid">20837516</pub-id>
</element-citation>
</ref>
<ref id="bib18">
<label>18</label>
<element-citation id="sref18" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamura</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Aberrant protein s-nitrosylation in neurodegenerative diseases</article-title>
<source/>Neuron
          <volume>78</volume>
<issue>4</issue>
<year>2013</year>
<fpage>596</fpage>
<lpage>614</lpage>
<pub-id pub-id-type="pmid">23719160</pub-id>
</element-citation>
</ref>
<ref id="bib19">
<label>19</label>
<element-citation id="sref19" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amal</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Shank3 mutation in a mouse model of autism leads to changes in the S-nitroso-proteome and affects key proteins involved in vesicle release and synaptic function</article-title>
<source/>Mol. Psychiatr.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1038/s41380-018-0113-6</pub-id>
</element-citation>
</ref>
<ref id="bib20">
<label>20</label>
<element-citation id="sref20" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lipton</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>S-Nitrosylation in neurogenesis and neuronal development</article-title>
<source/>Biochim. Biophys. Acta
          <volume>1850</volume>
<issue>8</issue>
<year>2015</year>
<fpage>1588</fpage>
<lpage>1593</lpage>
<pub-id pub-id-type="pmid">25527866</pub-id>
</element-citation>
</ref>
<ref id="bib21">
<label>21</label>
<element-citation id="sref21" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canossa</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Nitric oxide down-regulates brain-derived neurotrophic factor secretion in cultured hippocampal neurons</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>99</volume>
<issue>5</issue>
<year>2002</year>
<fpage>3282</fpage>
<lpage>3287</lpage>
<pub-id pub-id-type="pmid">11867712</pub-id>
</element-citation>
</ref>
<ref id="bib22">
<label>22</label>
<element-citation id="sref22" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riccio</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>A nitric oxide signaling pathway controls CREB-mediated gene expression in neurons</article-title>
<source/>Mol. Cell.
          <volume>21</volume>
<issue>2</issue>
<year>2006</year>
<fpage>283</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="pmid">16427017</pub-id>
</element-citation>
</ref>
<ref id="bib23">
<label>23</label>
<element-citation id="sref23" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Neurotrophin-mediated degradation of histone methyltransferase by S-nitrosylation cascade regulates neuronal differentiation</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>108</volume>
<issue>50</issue>
<year>2011</year>
<fpage>20178</fpage>
<lpage>20183</lpage>
<pub-id pub-id-type="pmid">22123949</pub-id>
</element-citation>
</ref>
<ref id="bib24">
<label>24</label>
<element-citation id="sref24" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hara</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding</article-title>
<source/>Nat. Cell Biol.
          <volume>7</volume>
<issue>7</issue>
<year>2005</year>
<fpage>665</fpage>
<lpage>674</lpage>
<pub-id pub-id-type="pmid">15951807</pub-id>
</element-citation>
</ref>
<ref id="bib25">
<label>25</label>
<element-citation id="sref25" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects</article-title>
<source/>Neuropharmacology
          <volume>116</volume>
<year>2017</year>
<fpage>260</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="pmid">28065587</pub-id>
</element-citation>
</ref>
<ref id="bib26">
<label>26</label>
<element-citation id="sref26" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>West</surname>
<given-names>A.E.</given-names>
</name>
</person-group>
<article-title>Calcium regulation of neuronal gene expression</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>98</volume>
<issue>20</issue>
<year>2001</year>
<fpage>11024</fpage>
<lpage>11031</lpage>
<pub-id pub-id-type="pmid">11572963</pub-id>
</element-citation>
</ref>
<ref id="bib27">
<label>27</label>
<element-citation id="sref27" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>McFadden</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB</article-title>
<source/>Neuron
          <volume>4</volume>
<issue>4</issue>
<year>1990</year>
<fpage>571</fpage>
<lpage>582</lpage>
<pub-id pub-id-type="pmid">2157471</pub-id>
</element-citation>
</ref>
<ref id="bib28">
<label>28</label>
<element-citation id="sref28" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayr</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Montminy</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Transcriptional regulation by the phosphorylation-dependent factor CREB</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <volume>2</volume>
<issue>8</issue>
<year>2001</year>
<fpage>599</fpage>
<lpage>609</lpage>
<pub-id pub-id-type="pmid">11483993</pub-id>
</element-citation>
</ref>
<ref id="bib29">
<label>29</label>
<element-citation id="sref29" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>cAMP response element-binding protein (CREB): a possible signaling molecule link in the pathophysiology of schizophrenia</article-title>
<source/>Front. Mol. Neurosci.
          <volume>11</volume>
<issue>255</issue>
<year>2018</year>
</element-citation>
</ref>
<ref id="bib30">
<label>30</label>
<element-citation id="sref30" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dyson</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>P.E.</given-names>
</name>
</person-group>
<article-title>Role of intrinsic protein disorder in the function and interactions of the transcriptional coactivators CREB-binding protein (CBP) and p300</article-title>
<source/>J. Biol. Chem.
          <volume>291</volume>
<issue>13</issue>
<year>2016</year>
<fpage>6714</fpage>
<lpage>6722</lpage>
<pub-id pub-id-type="pmid">26851278</pub-id>
</element-citation>
</ref>
<ref id="bib31">
<label>31</label>
<element-citation id="sref31" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sen</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>GOSPEL: a neuroprotective protein that binds to GAPDH upon S-nitrosylation</article-title>
<source/>Neuron
          <volume>63</volume>
<issue>1</issue>
<year>2009</year>
<fpage>81</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">19607794</pub-id>
</element-citation>
</ref>
<ref id="bib32">
<label>32</label>
<element-citation id="sref32" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kornberg</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>GAPDH mediates nitrosylation of nuclear proteins</article-title>
<source/>Nat. Cell Biol.
          <volume>12</volume>
<issue>11</issue>
<year>2010</year>
<fpage>1094</fpage>
<lpage>1100</lpage>
<pub-id pub-id-type="pmid">20972425</pub-id>
</element-citation>
</ref>
<ref id="bib33">
<label>33</label>
<element-citation id="sref33" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S.B.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of B23/nucleophosmin by GAPDH protects cells from the SIAH1-GAPDH death cascade</article-title>
<source/>J. Cell Biol.
          <volume>199</volume>
<issue>1</issue>
<year>2012</year>
<fpage>65</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">23027902</pub-id>
</element-citation>
</ref>
<ref id="bib34">
<label>34</label>
<element-citation id="sref34" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nott</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons</article-title>
<source/>Nature
          <volume>455</volume>
<issue>7211</issue>
<year>2008</year>
<fpage>411</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="pmid">18754010</pub-id>
</element-citation>
</ref>
<ref id="bib35">
<label>35</label>
<element-citation id="sref35" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C.V.</given-names>
</name>
<name>
<surname>McLoon</surname>
<given-names>S.C.</given-names>
</name>
</person-group>
<article-title>Involvement of nitric oxide in the elimination of a transient retinotectal projection in development</article-title>
<source/>Science
          <volume>265</volume>
<issue>5178</issue>
<year>1994</year>
<fpage>1593</fpage>
<lpage>1596</lpage>
<pub-id pub-id-type="pmid">7521541</pub-id>
</element-citation>
</ref>
<ref id="bib36">
<label>36</label>
<element-citation id="sref36" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stroissnigg</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of microtubule-associated protein 1B mediates nitric-oxide-induced axon retraction</article-title>
<source/>Nat. Cell Biol.
          <volume>9</volume>
<issue>9</issue>
<year>2007</year>
<fpage>1035</fpage>
<lpage>1045</lpage>
<pub-id pub-id-type="pmid">17704770</pub-id>
</element-citation>
</ref>
<ref id="bib37">
<label>37</label>
<element-citation id="sref37" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Packer</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Nitric oxide negatively regulates mammalian adult neurogenesis</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>100</volume>
<issue>16</issue>
<year>2003</year>
<fpage>9566</fpage>
<lpage>9571</lpage>
<pub-id pub-id-type="pmid">12886012</pub-id>
</element-citation>
</ref>
<ref id="bib38">
<label>38</label>
<element-citation id="sref38" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moreno-Lopez</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Nitric oxide is a physiological inhibitor of neurogenesis in the adult mouse subventricular zone and olfactory bulb</article-title>
<source/>J. Neurosci.
          <volume>24</volume>
<issue>1</issue>
<year>2004</year>
<fpage>85</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="pmid">14715941</pub-id>
</element-citation>
</ref>
<ref id="bib39">
<label>39</label>
<element-citation id="sref39" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torroglosa</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Nitric oxide decreases subventricular zone stem cell proliferation by inhibition of epidermal growth factor receptor and phosphoinositide-3-kinase/Akt pathway</article-title>
<source/>Stem Cell.
          <volume>25</volume>
<issue>1</issue>
<year>2007</year>
<fpage>88</fpage>
<lpage>97</lpage>
</element-citation>
</ref>
<ref id="bib40">
<label>40</label>
<element-citation id="sref40" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahay</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation</article-title>
<source/>Nature
          <volume>472</volume>
<issue>7344</issue>
<year>2011</year>
<fpage>466</fpage>
<lpage>470</lpage>
<pub-id pub-id-type="pmid">21460835</pub-id>
</element-citation>
</ref>
<ref id="bib41">
<label>41</label>
<element-citation id="sref41" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamoto</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation-mediated redox transcriptional switch modulates neurogenesis and neuronal cell death</article-title>
<source/>Cell Rep.
          <volume>8</volume>
<issue>1</issue>
<year>2014</year>
<fpage>217</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="pmid">25001280</pub-id>
</element-citation>
</ref>
<ref id="bib42">
<label>42</label>
<element-citation id="sref42" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murai</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Nuclear receptor TLX stimulates hippocampal neurogenesis and enhances learning and memory in a transgenic mouse model</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>111</volume>
<issue>25</issue>
<year>2014</year>
<fpage>9115</fpage>
<lpage>9120</lpage>
<pub-id pub-id-type="pmid">24927526</pub-id>
</element-citation>
</ref>
<ref id="bib43">
<label>43</label>
<element-citation id="sref43" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inglis</surname>
<given-names>F.M.</given-names>
</name>
</person-group>
<article-title>The role of nitric oxide and NMDA receptors in the development of motor neuron dendrites</article-title>
<source/>J. Neurosci.
          <volume>18</volume>
<issue>24</issue>
<year>1998</year>
<fpage>10493</fpage>
<lpage>10501</lpage>
<pub-id pub-id-type="pmid">9852587</pub-id>
</element-citation>
</ref>
<ref id="bib44">
<label>44</label>
<element-citation id="sref44" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lord</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorder</article-title>
<source/>Lancet
          <volume>392</volume>
<issue>10146</issue>
<year>2018</year>
<fpage>508</fpage>
<lpage>520</lpage>
<pub-id pub-id-type="pmid">30078460</pub-id>
</element-citation>
</ref>
<ref id="bib45">
<label>45</label>
<element-citation id="sref45" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>iTRAQ-Based proteomic analysis reveals protein profile in plasma from children with autism</article-title>
<source/>Proteonomics Clin. Appl.
          <volume>12</volume>
<issue>3</issue>
<year>2018</year>
<object-id pub-id-type="publisher-id">e1700085</object-id>
</element-citation>
</ref>
<ref id="bib46">
<label>46</label>
<element-citation id="sref46" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elsabbagh</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Global prevalence of autism and other pervasive developmental disorders</article-title>
<source/>Autism Res.
          <volume>5</volume>
<issue>3</issue>
<year>2012</year>
<fpage>160</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="pmid">22495912</pub-id>
</element-citation>
</ref>
<ref id="bib47">
<label>47</label>
<element-citation id="sref47" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyall</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>The changing epidemiology of autism spectrum disorders</article-title>
<source/>Annu. Rev. Publ. Health
          <volume>38</volume>
<year>2017</year>
<fpage>81</fpage>
<lpage>102</lpage>
</element-citation>
</ref>
<ref id="bib48">
<label>48</label>
<element-citation id="sref48" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drapeau</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Behavioral phenotyping of an improved mouse model of phelan-McDermid syndrome with a complete deletion of the Shank3 gene</article-title>
<source/>eNeuro
          <volume>5</volume>
<issue>3</issue>
<year>2018</year>
</element-citation>
</ref>
<ref id="bib49">
<label>49</label>
<element-citation id="sref49" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monteiro</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>SHANK proteins: roles at the synapse and in autism spectrum disorder</article-title>
<source/>Nat. Rev. Neurosci.
          <volume>18</volume>
<issue>3</issue>
<year>2017</year>
<fpage>147</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="pmid">28179641</pub-id>
</element-citation>
</ref>
<ref id="bib50">
<label>50</label>
<element-citation id="sref50" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peca</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Shank3 mutant mice display autistic-like behaviours and striatal dysfunction</article-title>
<source/>Nature
          <volume>472</volume>
<issue>7344</issue>
<year>2011</year>
<fpage>437</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="pmid">21423165</pub-id>
</element-citation>
</ref>
<ref id="bib51">
<label>51</label>
<element-citation id="sref51" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Mice with Shank3 mutations associated with ASD and schizophrenia display both shared and distinct defects</article-title>
<source/>Neuron
          <volume>89</volume>
<issue>1</issue>
<year>2016</year>
<fpage>147</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="pmid">26687841</pub-id>
</element-citation>
</ref>
<ref id="bib52">
<label>52</label>
<element-citation id="sref52" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Greengard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>Synaptic vesicle mobilization is regulated by distinct synapsin I phosphorylation pathways at different frequencies</article-title>
<source/>Neuron
          <volume>38</volume>
<issue>1</issue>
<year>2003</year>
<fpage>69</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="pmid">12691665</pub-id>
</element-citation>
</ref>
<ref id="bib53">
<label>53</label>
<element-citation id="sref53" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Cytoplasm-predominant Pten associates with increased region-specific brain tyrosine hydroxylase and dopamine D2 receptors in mouse model with autistic traits</article-title>
<source/>Mol. Autism.
          <volume>6</volume>
<year>2015</year>
<fpage>63</fpage>
<pub-id pub-id-type="pmid">26579216</pub-id>
</element-citation>
</ref>
<ref id="bib54">
<label>54</label>
<element-citation id="sref54" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmer</surname>
<given-names>Z.J.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of syntaxin 1 at Cys(145) is a regulatory switch controlling Munc18-1 binding</article-title>
<source/>Biochem. J.
          <volume>413</volume>
<issue>3</issue>
<year>2008</year>
<fpage>479</fpage>
<lpage>491</lpage>
<pub-id pub-id-type="pmid">18452404</pub-id>
</element-citation>
</ref>
<ref id="bib55">
<label>55</label>
<element-citation id="sref55" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitsikas</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>The role of nitric oxide donors in schizophrenia: basic studies and clinical applications</article-title>
<source/>Eur. J. Pharmacol.
          <volume>766</volume>
<year>2015</year>
<fpage>106</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="pmid">26435027</pub-id>
</element-citation>
</ref>
<ref id="bib56">
<label>56</label>
<element-citation id="sref56" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nasyrova</surname>
<given-names>R.F.</given-names>
</name>
</person-group>
<article-title>Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects</article-title>
<source/>Front. Physiol.
          <volume>6</volume>
<year>2015</year>
<fpage>139</fpage>
<pub-id pub-id-type="pmid">26029110</pub-id>
</element-citation>
</ref>
<ref id="bib57">
<label>57</label>
<element-citation id="sref57" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freedman</surname>
<given-names>R.</given-names>
</name>
</person-group>
<source/><italic>Schizophrenia.</italic> N Engl J Med
          <volume>349</volume>
<issue>18</issue>
<year>2003</year>
<fpage>1738</fpage>
<lpage>1749</lpage>
<pub-id pub-id-type="pmid">14585943</pub-id>
</element-citation>
</ref>
<ref id="bib58">
<label>58</label>
<element-citation id="sref58" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>R.D.</given-names>
</name>
</person-group>
<article-title>Increased nitric oxide radicals in postmortem brain from patients with schizophrenia</article-title>
<source/>Schizophr. Bull.
          <volume>30</volume>
<issue>4</issue>
<year>2004</year>
<fpage>923</fpage>
<lpage>934</lpage>
<pub-id pub-id-type="pmid">15954198</pub-id>
</element-citation>
</ref>
<ref id="bib59">
<label>59</label>
<element-citation id="sref59" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernstein</surname>
<given-names>H.G.</given-names>
</name>
</person-group>
<article-title>Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy</article-title>
<source/>CNS Neurol. Disord. - Drug Targets
          <volume>10</volume>
<issue>7</issue>
<year>2011</year>
<fpage>792</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="pmid">21999729</pub-id>
</element-citation>
</ref>
<ref id="bib60">
<label>60</label>
<element-citation id="sref60" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lorrain</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Hull</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>Nitric oxide increases dopamine and serotonin release in the medial preoptic area</article-title>
<source/>Neuroreport
          <volume>5</volume>
<issue>1</issue>
<year>1993</year>
<fpage>87</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="pmid">8280866</pub-id>
</element-citation>
</ref>
<ref id="bib61">
<label>61</label>
<element-citation id="sref61" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brenman</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Bredt</surname>
<given-names>D.S.</given-names>
</name>
</person-group>
<article-title>Synaptic signaling by nitric oxide</article-title>
<source/>Curr. Opin. Neurobiol.
          <volume>7</volume>
<issue>3</issue>
<year>1997</year>
<fpage>374</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="pmid">9232800</pub-id>
</element-citation>
</ref>
<ref id="bib62">
<label>62</label>
<element-citation id="sref62" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Javitt</surname>
<given-names>D.C.</given-names>
</name>
</person-group>
<article-title>Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions</article-title>
<source/>Int. Rev. Neurobiol.
          <volume>78</volume>
<year>2007</year>
<fpage>69</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="pmid">17349858</pub-id>
</element-citation>
</ref>
<ref id="bib63">
<label>63</label>
<element-citation id="sref63" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reif</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function</article-title>
<source/>Mol. Psychiatr.
          <volume>11</volume>
<issue>3</issue>
<year>2006</year>
<fpage>286</fpage>
<lpage>300</lpage>
</element-citation>
</ref>
<ref id="bib64">
<label>64</label>
<element-citation id="sref64" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.K.</given-names>
</name>
</person-group>
<article-title>Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls</article-title>
<source/>Schizophr. Res.
          <volume>104</volume>
<issue>1–3</issue>
<year>2008</year>
<fpage>36</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">18639442</pub-id>
</element-citation>
</ref>
<ref id="bib65">
<label>65</label>
<element-citation id="sref65" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramirez</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study</article-title>
<source/>Schizophr. Res.
          <volume>68</volume>
<issue>2–3</issue>
<year>2004</year>
<fpage>357</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="pmid">15099617</pub-id>
</element-citation>
</ref>
<ref id="bib66">
<label>66</label>
<element-citation id="sref66" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakano</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study</article-title>
<source/>Hum. Psychopharmacol.
          <volume>25</volume>
<issue>2</issue>
<year>2010</year>
<fpage>139</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="pmid">20196178</pub-id>
</element-citation>
</ref>
<ref id="bib67">
<label>67</label>
<element-citation id="sref67" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirchner</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Impaired cognitive performance in neuronal nitric oxide synthase knockout mice is associated with hippocampal protein derangements</article-title>
<source/>Nitric Oxide
          <volume>11</volume>
<issue>4</issue>
<year>2004</year>
<fpage>316</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="pmid">15604044</pub-id>
</element-citation>
</ref>
<ref id="bib68">
<label>68</label>
<element-citation id="sref68" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallak</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial</article-title>
<source/>JAMA Psychiatry
          <volume>70</volume>
<issue>7</issue>
<year>2013</year>
<fpage>668</fpage>
<lpage>676</lpage>
<pub-id pub-id-type="pmid">23699763</pub-id>
</element-citation>
</ref>
<ref id="bib69">
<label>69</label>
<element-citation id="sref69" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maia-de-Oliveira</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>The effects of sodium nitroprusside treatment on cognitive deficits in schizophrenia: a pilot study</article-title>
<source/>J. Clin. Psychopharmacol.
          <volume>35</volume>
<issue>1</issue>
<year>2015</year>
<fpage>83</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">25502490</pub-id>
</element-citation>
</ref>
<ref id="bib70">
<label>70</label>
<element-citation id="sref70" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Q.G.</given-names>
</name>
</person-group>
<article-title>Neuronal nitric oxide synthase and affective disorders</article-title>
<source/>IBRO Rep
          <volume>5</volume>
<year>2018</year>
<fpage>116</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="pmid">30591953</pub-id>
</element-citation>
</ref>
<ref id="bib71">
<label>71</label>
<element-citation id="sref71" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vieta</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Bipolar disorders</article-title>
<source/>Nat. Rev. Dis.Prim.
          <volume>4</volume>
<issue>1</issue>
<year>2018</year>
<fpage>18008</fpage>
<pub-id pub-id-type="pmid">29516993</pub-id>
</element-citation>
</ref>
<ref id="bib72">
<label>72</label>
<element-citation id="sref72" publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Force</surname>
<given-names>D.-T.</given-names>
</name>
</person-group>
<source/>Diagnostic and Statistical Manual of Mental Disorders
          <edition>fifth ed.</edition>
<year>2013</year>
<publisher-name>American Psychiatric Association Publishing</publisher-name>
<comment>(DSM-5). Fifith Edition</comment>
</element-citation>
</ref>
<ref id="bib73">
<label>73</label>
<element-citation id="sref73" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarate</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Manji</surname>
<given-names>H.K.</given-names>
</name>
</person-group>
<article-title>Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder</article-title>
<source/>Biol. Psychiatr.
          <volume>59</volume>
<issue>11</issue>
<year>2006</year>
<fpage>1006</fpage>
<lpage>1020</lpage>
</element-citation>
</ref>
<ref id="bib74">
<label>74</label>
<element-citation id="sref74" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baggott</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A.N.</given-names>
</name>
</person-group>
<article-title>Sildenafil-induced relapse in bipolar disorder: is nitric oxide the mechanism?</article-title>
<source/>Int. J. Neuropsychopharmacol.
          <volume>7</volume>
<issue>4</issue>
<year>2004</year>
<fpage>525</fpage>
<pub-id pub-id-type="pmid">15458609</pub-id>
</element-citation>
</ref>
<ref id="bib75">
<label>75</label>
<element-citation id="sref75" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fontoura</surname>
<given-names>P.C.</given-names>
</name>
</person-group>
<article-title>Defective nitric oxide-cyclic guanosine monophosphate signaling in patients with bipolar disorder: a potential role for platelet dysfunction</article-title>
<source/>Psychosom. Med.
          <volume>74</volume>
<issue>8</issue>
<year>2012</year>
<fpage>873</fpage>
<lpage>877</lpage>
<pub-id pub-id-type="pmid">23023680</pub-id>
</element-citation>
</ref>
<ref id="bib76">
<label>76</label>
<element-citation id="sref76" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Sousa</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>Lithium increases nitric oxide levels in subjects with bipolar disorder during depressive episodes</article-title>
<source/>J. Psychiatr. Res.
          <volume>55</volume>
<year>2014</year>
<fpage>96</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="pmid">24768108</pub-id>
</element-citation>
</ref>
<ref id="bib77">
<label>77</label>
<element-citation id="sref77" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savas</surname>
<given-names>H.A.</given-names>
</name>
</person-group>
<article-title>Possible role of nitric oxide and adrenomedullin in bipolar affective disorder</article-title>
<source/>Neuropsychobiology
          <volume>45</volume>
<issue>2</issue>
<year>2002</year>
<fpage>57</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">11893860</pub-id>
</element-citation>
</ref>
<ref id="bib78">
<label>78</label>
<element-citation id="sref78" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreazza</surname>
<given-names>A.C.</given-names>
</name>
</person-group>
<article-title>Oxidative stress markers in bipolar disorder: a meta-analysis</article-title>
<source/>J. Affect. Disord.
          <volume>111</volume>
<issue>2</issue>
<year>2008</year>
<fpage>135</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="pmid">18539338</pub-id>
</element-citation>
</ref>
<ref id="bib79">
<label>79</label>
<element-citation id="sref79" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dodick</surname>
<given-names>D.W.</given-names>
</name>
</person-group>
<article-title>Migraine</article-title>
<source/>Lancet
          <volume>391</volume>
<issue>10127</issue>
<year>2018</year>
<fpage>1315</fpage>
<lpage>1330</lpage>
<pub-id pub-id-type="pmid">29523342</pub-id>
</element-citation>
</ref>
<ref id="bib80">
<label>80</label>
<element-citation id="sref80" publication-type="journal">
<article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015</article-title>
<source/>Lancet
          <volume>388</volume>
<year>2016</year>
<fpage>1545</fpage>
<lpage>1602</lpage>
<pub-id pub-id-type="pmid">27733282</pub-id>
</element-citation>
</ref>
<ref id="bib81">
<label>81</label>
<element-citation id="sref81" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarchielli</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks</article-title>
<source/>Cephalalgia
          <volume>20</volume>
<issue>10</issue>
<year>2000</year>
<fpage>907</fpage>
<lpage>918</lpage>
<pub-id pub-id-type="pmid">11304026</pub-id>
</element-citation>
</ref>
<ref id="bib82">
<label>82</label>
<element-citation id="sref82" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neeb</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Reuter</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Nitric oxide in migraine</article-title>
<source/>CNS Neurol. Disord. - Drug Targets
          <volume>6</volume>
<issue>4</issue>
<year>2007</year>
<fpage>258</fpage>
<lpage>264</lpage>
<pub-id pub-id-type="pmid">17691982</pub-id>
</element-citation>
</ref>
<ref id="bib83">
<label>83</label>
<element-citation id="sref83" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fozard</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>The 5-hydroxytryptamine-nitric oxide connection: the key link in the initiation of migraine?</article-title>
<source/>Arch. Int. Pharmacodyn. Ther.
          <volume>329</volume>
<issue>1</issue>
<year>1995</year>
<fpage>111</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="pmid">7639613</pub-id>
</element-citation>
</ref>
<ref id="bib84">
<label>84</label>
<element-citation id="sref84" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glusa</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Richter</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Endothelium-dependent relaxation of porcine pulmonary arteries via 5-HT1C-like receptors</article-title>
<source/>Naunyn-Schmiedeberg’s Arch. Pharmacol.
          <volume>347</volume>
<issue>5</issue>
<year>1993</year>
<fpage>471</fpage>
<lpage>477</lpage>
<pub-id pub-id-type="pmid">8391650</pub-id>
</element-citation>
</ref>
<ref id="bib85">
<label>85</label>
<element-citation id="sref85" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Nitric oxide synthesis inhibitors attenuate calcitonin gene-related peptide endothelium-dependent vasorelaxation in rat aorta</article-title>
<source/>Eur. J. Pharmacol.
          <volume>212</volume>
<issue>1</issue>
<year>1992</year>
<fpage>37</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">1555637</pub-id>
</element-citation>
</ref>
<ref id="bib86">
<label>86</label>
<element-citation id="sref86" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woolf</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>S.W.</given-names>
</name>
</person-group>
<article-title>The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states</article-title>
<source/>Pain
          <volume>44</volume>
<issue>3</issue>
<year>1991</year>
<fpage>293</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="pmid">1828878</pub-id>
</element-citation>
</ref>
<ref id="bib87">
<label>87</label>
<element-citation id="sref87" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Kuy</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Lohman</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>The role of nitric oxide in vascular headache</article-title>
<source/>Pharm. World Sci.
          <volume>25</volume>
<issue>4</issue>
<year>2003</year>
<fpage>146</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="pmid">12964492</pub-id>
</element-citation>
</ref>
<ref id="bib88">
<label>88</label>
<element-citation id="sref88" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olesen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Iversen</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Thomsen</surname>
<given-names>L.L.</given-names>
</name>
</person-group>
<article-title>Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain</article-title>
<source/>Neuroreport
          <volume>4</volume>
<issue>8</issue>
<year>1993</year>
<fpage>1027</fpage>
<lpage>1030</lpage>
<pub-id pub-id-type="pmid">8241457</pub-id>
</element-citation>
</ref>
<ref id="bib89">
<label>89</label>
<element-citation id="sref89" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellantonio</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Haemodynamic correlates of early and delayed responses to sublingual administration of isosorbide dinitrate in migraine patients: a transcranial Doppler study</article-title>
<source/>Cephalalgia
          <volume>17</volume>
<issue>3</issue>
<year>1997</year>
<fpage>183</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="pmid">9170341</pub-id>
</element-citation>
</ref>
<ref id="bib90">
<label>90</label>
<element-citation id="sref90" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimomura</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Platelet nitric oxide metabolites in migraine</article-title>
<source/>Cephalalgia
          <volume>19</volume>
<issue>4</issue>
<year>1999</year>
<fpage>218</fpage>
<lpage>222</lpage>
<pub-id pub-id-type="pmid">10376166</pub-id>
</element-citation>
</ref>
<ref id="bib91">
<label>91</label>
<element-citation id="sref91" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knyihar-Csillik</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vecsei</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Effect of a nitric oxide donor on nitroxergic nerve fibers in the rat dura mater</article-title>
<source/>Neurosci. Lett.
          <volume>260</volume>
<issue>2</issue>
<year>1999</year>
<fpage>97</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="pmid">10025708</pub-id>
</element-citation>
</ref>
<ref id="bib92">
<label>92</label>
<element-citation id="sref92" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Read</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Enhanced nitric oxide release during cortical spreading depression following infusion of glyceryl trinitrate in the anaesthetized cat</article-title>
<source/>Cephalalgia
          <volume>17</volume>
<issue>3</issue>
<year>1997</year>
<fpage>159</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="pmid">9170338</pub-id>
</element-citation>
</ref>
<ref id="bib93">
<label>93</label>
<element-citation id="sref93" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Read</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Effects of sumatriptan on nitric oxide and superoxide balance during glyceryl trinitrate infusion in the rat. Implications for antimigraine mechanisms</article-title>
<source/>Brain Res.
          <volume>847</volume>
<issue>1</issue>
<year>1999</year>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">10564729</pub-id>
</element-citation>
</ref>
<ref id="bib94">
<label>94</label>
<element-citation id="sref94" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kruuse</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects</article-title>
<source/>J. Cerebr. Blood Flow Metabol.
          <volume>22</volume>
<issue>9</issue>
<year>2002</year>
<fpage>1124</fpage>
<lpage>1131</lpage>
</element-citation>
</ref>
<ref id="bib95">
<label>95</label>
<element-citation id="sref95" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lassen</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Thomsen</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Olesen</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine</article-title>
<source/>Neuroreport
          <volume>6</volume>
<issue>11</issue>
<year>1995</year>
<fpage>1475</fpage>
<lpage>1479</lpage>
<pub-id pub-id-type="pmid">7579128</pub-id>
</element-citation>
</ref>
<ref id="bib96">
<label>96</label>
<element-citation id="sref96" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayajiki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Toda</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Involvement of nitric oxide in endothelium-dependent, phasic relaxation caused by histamine in monkey cerebral arteries</article-title>
<source/>Jpn. J. Pharmacol.
          <volume>60</volume>
<issue>4</issue>
<year>1992</year>
<fpage>357</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="pmid">1287271</pub-id>
</element-citation>
</ref>
<ref id="bib97">
<label>97</label>
<element-citation id="sref97" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lassen</surname>
<given-names>L.H.</given-names>
</name>
</person-group>
<article-title>Nitric oxide synthase inhibition in migraine</article-title>
<source/>Lancet
          <volume>349</volume>
<issue>9049</issue>
<year>1997</year>
<fpage>401</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="pmid">9033475</pub-id>
</element-citation>
</ref>
<ref id="bib98">
<label>98</label>
<element-citation id="sref98" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devinsky</surname>
<given-names>O.</given-names>
</name>
</person-group>
<source/><italic>Epilepsy.</italic> Nat Rev Dis Primers
          <volume>4</volume>
<year>2018</year>
<fpage>18024</fpage>
<pub-id pub-id-type="pmid">29722352</pub-id>
</element-citation>
</ref>
<ref id="bib99">
<label>99</label>
<element-citation id="sref99" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferraro</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sardo</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Nitric oxide and brain hyperexcitability</article-title>
<source/>In Vivo
          <volume>18</volume>
<issue>3</issue>
<year>2004</year>
<fpage>357</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="pmid">15341192</pub-id>
</element-citation>
</ref>
<ref id="bib100">
<label>100</label>
<element-citation id="sref100" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buisson</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Nitric oxide: an endogenous anticonvulsant substance</article-title>
<source/>Neuroreport
          <volume>4</volume>
<issue>4</issue>
<year>1993</year>
<fpage>444</fpage>
<lpage>446</lpage>
<pub-id pub-id-type="pmid">7684618</pub-id>
</element-citation>
</ref>
<ref id="bib101">
<label>101</label>
<element-citation id="sref101" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evora</surname>
<given-names>P.R.B.</given-names>
</name>
</person-group>
<article-title>Methylene blue is a guanylate cyclase inhibitor that does not interfere with nitric oxide synthesis</article-title>
<source/>Tex. Heart Inst. J.
          <volume>43</volume>
<issue>1</issue>
<year>2016</year>
<comment>103-103</comment>
</element-citation>
</ref>
<ref id="bib102">
<label>102</label>
<element-citation id="sref102" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herberg</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Grottick</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>I.C.</given-names>
</name>
</person-group>
<article-title>Nitric oxide synthesis, epileptic seizures and kindling</article-title>
<source/>Psychopharmacol. (Berl)
          <volume>119</volume>
<issue>1</issue>
<year>1995</year>
<fpage>115</fpage>
<lpage>123</lpage>
</element-citation>
</ref>
<ref id="bib103">
<label>103</label>
<element-citation id="sref103" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hrncic</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>The role of nitric oxide in homocysteine thiolactone-induced seizures in adult rats</article-title>
<source/>Cell. Mol. Neurobiol.
          <volume>30</volume>
<issue>2</issue>
<year>2010</year>
<fpage>219</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="pmid">19714460</pub-id>
</element-citation>
</ref>
<ref id="bib104">
<label>104</label>
<element-citation id="sref104" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Najm</surname>
<given-names>I.M.</given-names>
</name>
</person-group>
<article-title>Epileptogenicity correlated with increased N-methyl-D-aspartate receptor subunit NR2A/B in human focal cortical dysplasia</article-title>
<source/>Epilepsia
          <volume>41</volume>
<issue>8</issue>
<year>2000</year>
<fpage>971</fpage>
<lpage>976</lpage>
<pub-id pub-id-type="pmid">10961623</pub-id>
</element-citation>
</ref>
<ref id="bib105">
<label>105</label>
<element-citation id="sref105" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Martinez</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Neuronal nitric oxide synthase expression in resected epileptic dysplastic neocortex</article-title>
<source/>J. Neurosurg.
          <volume>110</volume>
<issue>2</issue>
<year>2009</year>
<fpage>343</fpage>
<lpage>349</lpage>
<pub-id pub-id-type="pmid">19245288</pub-id>
</element-citation>
</ref>
<ref id="bib106">
<label>106</label>
<element-citation id="sref106" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bashkatova</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>The influence of anticonvulsant and antioxidant drugs on nitric oxide level and lipid peroxidation in the rat brain during penthylenetetrazole-induced epileptiform model seizures</article-title>
<source/>Prog. Neuro-Psychopharmacol. Biol. Psychiatry
          <volume>27</volume>
<issue>3</issue>
<year>2003</year>
<fpage>487</fpage>
<lpage>492</lpage>
</element-citation>
</ref>
<ref id="bib108">
<label>108</label>
<element-citation id="sref108" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>Inhibition of the morphine withdrawal syndrome by a nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester</article-title>
<source/>Life Sci.
          <volume>52</volume>
<issue>22</issue>
<year>1993</year>
<fpage>Pl245</fpage>
<lpage>P249</lpage>
<pub-id pub-id-type="pmid">7684108</pub-id>
</element-citation>
</ref>
<ref id="bib109">
<label>109</label>
<element-citation id="sref109" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimes</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Vaupel</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>London</surname>
<given-names>E.D.</given-names>
</name>
</person-group>
<article-title>Attenuation of some signs of opioid withdrawal by inhibitors of nitric oxide synthase</article-title>
<source/>Psychopharmacol. (Berl)
          <volume>112</volume>
<issue>4</issue>
<year>1993</year>
<fpage>521</fpage>
<lpage>524</lpage>
</element-citation>
</ref>
<ref id="bib110">
<label>110</label>
<element-citation id="sref110" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuellar</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal</article-title>
<source/>Psychopharmacol. (Berl)
          <volume>148</volume>
<issue>1</issue>
<year>2000</year>
<fpage>66</fpage>
<lpage>73</lpage>
</element-citation>
</ref>
<ref id="bib111">
<label>111</label>
<element-citation id="sref111" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muriach</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate</article-title>
<source/>J. Neurochem.
          <volume>114</volume>
<issue>3</issue>
<year>2010</year>
<fpage>675</fpage>
<lpage>684</lpage>
<pub-id pub-id-type="pmid">20477932</pub-id>
</element-citation>
</ref>
<ref id="bib112">
<label>112</label>
<element-citation id="sref112" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beiser</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Chronic treatment with Tempol during acquisition or withdrawal from CPP abolishes the expression of cocaine reward and diminishes oxidative damage</article-title>
<source/>Sci. Rep.
          <volume>7</volume>
<issue>1</issue>
<year>2017</year>
<fpage>11162</fpage>
<pub-id pub-id-type="pmid">28894248</pub-id>
</element-citation>
</ref>
<ref id="bib113">
<label>113</label>
<element-citation id="sref113" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knych</surname>
<given-names>E.T.</given-names>
</name>
</person-group>
<article-title>Ethanol inhibits nonadrenergic, noncholinergic neurotransmission in the anococcygeus muscle of the rat</article-title>
<source/>Alcohol Clin. Exp. Res.
          <volume>18</volume>
<issue>3</issue>
<year>1994</year>
<fpage>566</fpage>
<lpage>570</lpage>
<pub-id pub-id-type="pmid">7943656</pub-id>
</element-citation>
</ref>
<ref id="bib114">
<label>114</label>
<element-citation id="sref114" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>Effects of nitric oxide-related agents on alcohol narcosis</article-title>
<source/>Alcohol Clin. Exp. Res.
          <volume>18</volume>
<issue>4</issue>
<year>1994</year>
<fpage>969</fpage>
<lpage>975</lpage>
<pub-id pub-id-type="pmid">7526727</pub-id>
</element-citation>
</ref>
<ref id="bib115">
<label>115</label>
<element-citation id="sref115" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vassiljev</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>The effects of the nitric oxide synthase inhibitor 7-nitroindazole on ethanol pharmacokinetics in rats after acute and chronic ethanol administration</article-title>
<source/>Alcohol Alcohol
          <volume>33</volume>
<issue>6</issue>
<year>1998</year>
<fpage>609</fpage>
<lpage>615</lpage>
<pub-id pub-id-type="pmid">9872349</pub-id>
</element-citation>
</ref>
<ref id="bib116">
<label>116</label>
<element-citation id="sref116" publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Weller</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Budson</surname>
<given-names>A.</given-names>
</name>
</person-group>
<chapter-title>Current Understanding of Alzheimer's Disease Diagnosis and Treatment</chapter-title>
<year>2018</year>
<fpage>7</fpage>
<comment>F1000Res</comment>
</element-citation>
</ref>
<ref id="bib117">
<label>117</label>
<element-citation id="sref117" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cruz</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>L.H.</given-names>
</name>
</person-group>
<article-title>Cdk5 deregulation in the pathogenesis of Alzheimer's disease</article-title>
<source/>Trends Mol. Med.
          <volume>10</volume>
<issue>9</issue>
<year>2004</year>
<fpage>452</fpage>
<lpage>458</lpage>
<pub-id pub-id-type="pmid">15350898</pub-id>
</element-citation>
</ref>
<ref id="bib118">
<label>118</label>
<element-citation id="sref118" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anggono</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Gotz</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Glutamate receptors in alzheimer's disease: mechanisms and therapies</article-title>
<source/>Neural Plast.
          <volume>2016</volume>
<year>2016</year>
<fpage>8256196</fpage>
<pub-id pub-id-type="pmid">27293907</pub-id>
</element-citation>
</ref>
<ref id="bib119">
<label>119</label>
<element-citation id="sref119" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seneviratne</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>S-nitrosation of proteins relevant to Alzheimer's disease during early stages of neurodegeneration</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>113</volume>
<issue>15</issue>
<year>2016</year>
<fpage>4152</fpage>
<lpage>4157</lpage>
<pub-id pub-id-type="pmid">27035958</pub-id>
</element-citation>
</ref>
<ref id="bib120">
<label>120</label>
<element-citation id="sref120" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernandez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Avila</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>GSK3 and tau: two convergence points in Alzheimer's disease</article-title>
<source/>J Alzheimers Dis
          <volume>33</volume>
<issue>Suppl 1</issue>
<year>2013</year>
<fpage>S141</fpage>
<lpage>S144</lpage>
<pub-id pub-id-type="pmid">22710914</pub-id>
</element-citation>
</ref>
<ref id="bib121">
<label>121</label>
<element-citation id="sref121" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zerbinatti</surname>
<given-names>C.V.</given-names>
</name>
<name>
<surname>Bu</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>LRP and Alzheimer's disease</article-title>
<source/>Rev. Neurosci.
          <volume>16</volume>
<issue>2</issue>
<year>2005</year>
<fpage>123</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">15959937</pub-id>
</element-citation>
</ref>
<ref id="bib122">
<label>122</label>
<element-citation id="sref122" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amal</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of E3 ubiquitin-protein ligase RNF213 alters non-canonical Wnt/Ca+2 signaling in the P301S mouse model of tauopathy</article-title>
<source/>Transl. Psychiatry
          <volume>9</volume>
<issue>1</issue>
<year>2019</year>
<fpage>44</fpage>
<pub-id pub-id-type="pmid">30696811</pub-id>
</element-citation>
</ref>
<ref id="bib123">
<label>123</label>
<element-citation id="sref123" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Odajima</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Cyclin E constrain Cdk5 activity to regulate synaptic plasticity and memory formation</article-title>
<source/>Dev. Cell
          <volume>21</volume>
<issue>4</issue>
<year>2011</year>
<fpage>655</fpage>
<lpage>668</lpage>
<pub-id pub-id-type="pmid">21944720</pub-id>
</element-citation>
</ref>
<ref id="bib124">
<label>124</label>
<element-citation id="sref124" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of cyclin-dependent kinase 5 (cdk5) regulates its kinase activity and dendrite growth during neuronal development</article-title>
<source/>J. Neurosci.
          <volume>30</volume>
<issue>43</issue>
<year>2010</year>
<fpage>14366</fpage>
<lpage>14370</lpage>
<pub-id pub-id-type="pmid">20980593</pub-id>
</element-citation>
</ref>
<ref id="bib125">
<label>125</label>
<element-citation id="sref125" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of Cdk5: potential implications in amyloid-beta-related neurotoxicity in Alzheimer disease</article-title>
<source/>Prion
          <volume>6</volume>
<issue>4</issue>
<year>2012</year>
<fpage>364</fpage>
<lpage>370</lpage>
<pub-id pub-id-type="pmid">22874667</pub-id>
</element-citation>
</ref>
<ref id="bib126">
<label>126</label>
<element-citation id="sref126" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by beta-amyloid peptide</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>108</volume>
<issue>34</issue>
<year>2011</year>
<fpage>14330</fpage>
<lpage>14335</lpage>
<pub-id pub-id-type="pmid">21844361</pub-id>
</element-citation>
</ref>
<ref id="bib127">
<label>127</label>
<element-citation id="sref127" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shankar</surname>
<given-names>G.M.</given-names>
</name>
</person-group>
<article-title>Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway</article-title>
<source/>J. Neurosci.
          <volume>27</volume>
<issue>11</issue>
<year>2007</year>
<fpage>2866</fpage>
<lpage>2875</lpage>
<pub-id pub-id-type="pmid">17360908</pub-id>
</element-citation>
</ref>
<ref id="bib128">
<label>128</label>
<element-citation id="sref128" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snyder</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>Regulation of NMDA receptor trafficking by amyloid-beta</article-title>
<source/>Nat. Neurosci.
          <volume>8</volume>
<issue>8</issue>
<year>2005</year>
<fpage>1051</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="pmid">16025111</pub-id>
</element-citation>
</ref>
<ref id="bib129">
<label>129</label>
<element-citation id="sref129" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors</article-title>
<source/>Nat. Neurosci.
          <volume>6</volume>
<issue>10</issue>
<year>2003</year>
<fpage>1039</fpage>
<lpage>1047</lpage>
<pub-id pub-id-type="pmid">14502288</pub-id>
</element-citation>
</ref>
<ref id="bib130">
<label>130</label>
<element-citation id="sref130" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury</article-title>
<source/>Science
          <volume>324</volume>
<issue>5923</issue>
<year>2009</year>
<fpage>102</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="pmid">19342591</pub-id>
</element-citation>
</ref>
<ref id="bib131">
<label>131</label>
<element-citation id="sref131" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Impaired balance of mitochondrial fission and fusion in Alzheimer's disease</article-title>
<source/>J. Neurosci.
          <volume>29</volume>
<issue>28</issue>
<year>2009</year>
<fpage>9090</fpage>
<lpage>9103</lpage>
<pub-id pub-id-type="pmid">19605646</pub-id>
</element-citation>
</ref>
<ref id="bib132">
<label>132</label>
<element-citation id="sref132" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Mitochondrial fission proteins in peripheral blood lymphocytes are potential biomarkers for Alzheimer's disease</article-title>
<source/>Eur. J. Neurol.
          <volume>19</volume>
<issue>7</issue>
<year>2012</year>
<fpage>1015</fpage>
<lpage>1022</lpage>
<pub-id pub-id-type="pmid">22340708</pub-id>
</element-citation>
</ref>
<ref id="bib133">
<label>133</label>
<element-citation id="sref133" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uehara</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration</article-title>
<source/>Nature
          <volume>441</volume>
<issue>7092</issue>
<year>2006</year>
<fpage>513</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="pmid">16724068</pub-id>
</element-citation>
</ref>
<ref id="bib134">
<label>134</label>
<element-citation id="sref134" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cordes</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation</article-title>
<source/>Biochem. Pharmacol.
          <volume>77</volume>
<issue>6</issue>
<year>2009</year>
<fpage>1064</fpage>
<lpage>1073</lpage>
<pub-id pub-id-type="pmid">19154729</pub-id>
</element-citation>
</ref>
<ref id="bib135">
<label>135</label>
<element-citation id="sref135" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>TMEM106B and APOE polymorphisms interact to confer risk for late-onset Alzheimer's disease in Han Chinese</article-title>
<source/>J. Neural. Transm.
          <volume>121</volume>
<issue>3</issue>
<year>2014</year>
<fpage>283</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="pmid">24166182</pub-id>
</element-citation>
</ref>
<ref id="bib136">
<label>136</label>
<element-citation id="sref136" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.C.</given-names>
</name>
</person-group>
<article-title>Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy</article-title>
<source/>Nat. Rev. Neurol.
          <volume>9</volume>
<issue>2</issue>
<year>2013</year>
<fpage>106</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="pmid">23296339</pub-id>
</element-citation>
</ref>
<ref id="bib137">
<label>137</label>
<element-citation id="sref137" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zahid</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Differential S-nitrosylation of proteins in Alzheimer's disease</article-title>
<source/>Neuroscience
          <volume>256</volume>
<year>2014</year>
<fpage>126</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="pmid">24157928</pub-id>
</element-citation>
</ref>
<ref id="bib138">
<label>138</label>
<element-citation id="sref138" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mhyre</surname>
<given-names>T.R.</given-names>
</name>
</person-group>
<article-title>Parkinson's disease</article-title>
<source/>Subcell. Biochem.
          <volume>65</volume>
<year>2012</year>
<fpage>389</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="pmid">23225012</pub-id>
</element-citation>
</ref>
<ref id="bib139">
<label>139</label>
<element-citation id="sref139" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalia</surname>
<given-names>L.V.</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>A.E.</given-names>
</name>
</person-group>
<article-title>Parkinson's disease</article-title>
<source/>Lancet
          <volume>386</volume>
<issue>9996</issue>
<year>2015</year>
<fpage>896</fpage>
<lpage>912</lpage>
<pub-id pub-id-type="pmid">25904081</pub-id>
</element-citation>
</ref>
<ref id="bib140">
<label>140</label>
<element-citation id="sref140" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>S.P.</given-names>
</name>
</person-group>
<article-title>Does restraining nitric oxide biosynthesis rescue from toxins-induced parkinsonism and sporadic Parkinson's disease?</article-title>
<source/>Mol. Neurobiol.
          <volume>49</volume>
<issue>1</issue>
<year>2014</year>
<fpage>262</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="pmid">23900742</pub-id>
</element-citation>
</ref>
<ref id="bib141">
<label>141</label>
<element-citation id="sref141" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jimenez-Jimenez</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>An update on the role of nitric oxide in the neurodegenerative processes of Parkinson's disease</article-title>
<source/>Curr. Med. Chem.
          <volume>23</volume>
<issue>24</issue>
<year>2016</year>
<fpage>2666</fpage>
<lpage>2679</lpage>
<pub-id pub-id-type="pmid">27776473</pub-id>
</element-citation>
</ref>
<ref id="bib142">
<label>142</label>
<element-citation id="sref142" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jenner</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group</article-title>
<source/>Ann. Neurol.
          <volume>32</volume>
<issue>Suppl</issue>
<year>1992</year>
<fpage>S82</fpage>
<lpage>S87</lpage>
<pub-id pub-id-type="pmid">1510385</pub-id>
</element-citation>
</ref>
<ref id="bib143">
<label>143</label>
<element-citation id="sref143" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pacher</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Beckman</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Liaudet</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Nitric oxide and peroxynitrite in health and disease</article-title>
<source/>Physiol. Rev.
          <volume>87</volume>
<issue>1</issue>
<year>2007</year>
<fpage>315</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="pmid">17237348</pub-id>
</element-citation>
</ref>
<ref id="bib144">
<label>144</label>
<element-citation id="sref144" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Souza</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies</article-title>
<source/>J. Biol. Chem.
          <volume>275</volume>
<issue>24</issue>
<year>2000</year>
<fpage>18344</fpage>
<lpage>18349</lpage>
<pub-id pub-id-type="pmid">10747881</pub-id>
</element-citation>
</ref>
<ref id="bib145">
<label>145</label>
<element-citation id="sref145" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giasson</surname>
<given-names>B.I.</given-names>
</name>
</person-group>
<article-title>Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions</article-title>
<source/>Science
          <volume>290</volume>
<issue>5493</issue>
<year>2000</year>
<fpage>985</fpage>
<lpage>989</lpage>
<pub-id pub-id-type="pmid">11062131</pub-id>
</element-citation>
</ref>
<ref id="bib146">
<label>146</label>
<element-citation id="sref146" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Przedborski</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease</article-title>
<source/>J. Neurochem.
          <volume>76</volume>
<issue>2</issue>
<year>2001</year>
<fpage>637</fpage>
<lpage>640</lpage>
<pub-id pub-id-type="pmid">11208927</pub-id>
</element-citation>
</ref>
<ref id="bib147">
<label>147</label>
<element-citation id="sref147" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>K.K.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function</article-title>
<source/>Science
          <volume>304</volume>
<issue>5675</issue>
<year>2004</year>
<fpage>1328</fpage>
<lpage>1331</lpage>
<pub-id pub-id-type="pmid">15105460</pub-id>
</element-citation>
</ref>
<ref id="bib148">
<label>148</label>
<element-citation id="sref148" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Transnitrosylation from DJ-1 to PTEN attenuates neuronal cell death in Parkinson's disease models</article-title>
<source/>J. Neurosci.
          <volume>34</volume>
<issue>45</issue>
<year>2014</year>
<fpage>15123</fpage>
<lpage>15131</lpage>
<pub-id pub-id-type="pmid">25378175</pub-id>
</element-citation>
</ref>
<ref id="bib149">
<label>149</label>
<element-citation id="sref149" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conway</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of the thioredoxin-like domains of protein disulfide isomerase and its role in neurodegenerative conditions</article-title>
<source/>Front Chem
          <volume>3</volume>
<year>2015</year>
<fpage>27</fpage>
<pub-id pub-id-type="pmid">25932462</pub-id>
</element-citation>
</ref>
<ref id="bib150">
<label>150</label>
<element-citation id="sref150" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsang</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>106</volume>
<issue>12</issue>
<year>2009</year>
<fpage>4900</fpage>
<lpage>4905</lpage>
<pub-id pub-id-type="pmid">19273858</pub-id>
</element-citation>
</ref>
<ref id="bib151">
<label>151</label>
<element-citation id="sref151" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>104</volume>
<issue>47</issue>
<year>2007</year>
<fpage>18742</fpage>
<lpage>18747</lpage>
<pub-id pub-id-type="pmid">18003920</pub-id>
</element-citation>
</ref>
<ref id="bib152">
<label>152</label>
<element-citation id="sref152" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>101</volume>
<issue>29</issue>
<year>2004</year>
<fpage>10810</fpage>
<lpage>10814</lpage>
<pub-id pub-id-type="pmid">15252205</pub-id>
</element-citation>
</ref>
<ref id="bib153">
<label>153</label>
<element-citation id="sref153" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipton</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Comment on "S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function</article-title>
<source/>Science
          <volume>308</volume>
<issue>5730</issue>
<year>2005</year>
<fpage>1870</fpage>
<comment>author reply 1870</comment>
<pub-id pub-id-type="pmid">15976289</pub-id>
</element-citation>
</ref>
<ref id="bib154">
<label>154</label>
<element-citation id="sref154" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreu</surname>
<given-names>C.I.</given-names>
</name>
</person-group>
<article-title>Protein disulfide isomerases in neurodegeneration: from disease mechanisms to biomedical applications</article-title>
<source/>FEBS (Fed. Eur. Biochem. Soc.) Lett.
          <volume>586</volume>
<issue>18</issue>
<year>2012</year>
<fpage>2826</fpage>
<lpage>2834</lpage>
</element-citation>
</ref>
<ref id="bib155">
<label>155</label>
<element-citation id="sref155" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>A.K.</given-names>
</name>
</person-group>
<article-title>Protein disulphide isomerase protects against protein aggregation and is S-nitrosylated in amyotrophic lateral sclerosis</article-title>
<source/>Brain
          <volume>133</volume>
<issue>Pt 1</issue>
<year>2010</year>
<fpage>105</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="pmid">19903735</pub-id>
</element-citation>
</ref>
<ref id="bib156">
<label>156</label>
<element-citation id="sref156" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deveraux</surname>
<given-names>Q.L.</given-names>
</name>
</person-group>
<article-title>Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases</article-title>
<source/>EMBO J.
          <volume>18</volume>
<issue>19</issue>
<year>1999</year>
<fpage>5242</fpage>
<lpage>5251</lpage>
<pub-id pub-id-type="pmid">10508158</pub-id>
</element-citation>
</ref>
<ref id="bib157">
<label>157</label>
<element-citation id="sref157" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamura</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death</article-title>
<source/>Mol. Cell.
          <volume>39</volume>
<issue>2</issue>
<year>2010</year>
<fpage>184</fpage>
<lpage>195</lpage>
<pub-id pub-id-type="pmid">20670888</pub-id>
</element-citation>
</ref>
<ref id="bib158">
<label>158</label>
<element-citation id="sref158" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rhee</surname>
<given-names>S.G.</given-names>
</name>
</person-group>
<article-title>Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins</article-title>
<source/>Curr. Opin. Cell Biol.
          <volume>17</volume>
<issue>2</issue>
<year>2005</year>
<fpage>183</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="pmid">15780595</pub-id>
</element-citation>
</ref>
<ref id="bib159">
<label>159</label>
<element-citation id="sref159" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Matteo</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study</article-title>
<source/>Ann. N. Y. Acad. Sci.
          <volume>1155</volume>
<year>2009</year>
<fpage>309</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="pmid">19250222</pub-id>
</element-citation>
</ref>
<ref id="bib160">
<label>160</label>
<element-citation id="sref160" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuste</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>7-Nitroindazole down-regulates dopamine/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson's disease</article-title>
<source/>Neuropharmacology
          <volume>63</volume>
<issue>7</issue>
<year>2012</year>
<fpage>1258</fpage>
<lpage>1267</lpage>
<pub-id pub-id-type="pmid">22877786</pub-id>
</element-citation>
</ref>
<ref id="bib161">
<label>161</label>
<element-citation id="sref161" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bashkatova</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain</article-title>
<source/>Exp. Neurol.
          <volume>186</volume>
<issue>2</issue>
<year>2004</year>
<fpage>235</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="pmid">15026259</pub-id>
</element-citation>
</ref>
<ref id="bib162">
<label>162</label>
<element-citation id="sref162" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>S.P.</given-names>
</name>
</person-group>
<article-title>Involvement of nitric oxide in maneb- and paraquat-induced Parkinson's disease phenotype in mouse: is there any link with lipid peroxidation?</article-title>
<source/>Neurochem. Res.
          <volume>35</volume>
<issue>8</issue>
<year>2010</year>
<fpage>1206</fpage>
<lpage>1213</lpage>
<pub-id pub-id-type="pmid">20455021</pub-id>
</element-citation>
</ref>
<ref id="bib163">
<label>163</label>
<element-citation id="sref163" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liberatore</surname>
<given-names>G.T.</given-names>
</name>
</person-group>
<article-title>Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease</article-title>
<source/>Nat. Med.
          <volume>5</volume>
<issue>12</issue>
<year>1999</year>
<fpage>1403</fpage>
<lpage>1409</lpage>
<pub-id pub-id-type="pmid">10581083</pub-id>
</element-citation>
</ref>
<ref id="bib164">
<label>164</label>
<element-citation id="sref164" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurosaki</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Role of nitric oxide synthase against MPTP neurotoxicity in mice</article-title>
<source/>Neurol. Res.
          <volume>24</volume>
<issue>7</issue>
<year>2002</year>
<fpage>655</fpage>
<lpage>662</lpage>
<pub-id pub-id-type="pmid">12392201</pub-id>
</element-citation>
</ref>
<ref id="bib165">
<label>165</label>
<element-citation id="sref165" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dikshit</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Involvement of the mitochondrial apoptotic pathway and nitric oxide synthase in dopaminergic neuronal death induced by 6-hydroxydopamine and lipopolysaccharide</article-title>
<source/>Redox Rep.
          <volume>15</volume>
<issue>3</issue>
<year>2010</year>
<fpage>115</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="pmid">20594414</pub-id>
</element-citation>
</ref>
<ref id="bib166">
<label>166</label>
<element-citation id="sref166" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease</article-title>
<source/>Redox Rep.
          <volume>10</volume>
<issue>2</issue>
<year>2005</year>
<fpage>103</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">15949131</pub-id>
</element-citation>
</ref>
<ref id="bib167">
<label>167</label>
<element-citation id="sref167" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broom</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease</article-title>
<source/>Free Radic. Biol. Med.
          <volume>50</volume>
<issue>5</issue>
<year>2011</year>
<fpage>633</fpage>
<lpage>640</lpage>
<pub-id pub-id-type="pmid">21185368</pub-id>
</element-citation>
</ref>
<ref id="bib168">
<label>168</label>
<element-citation id="sref168" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yadav</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis</article-title>
<source/>Mol. Neurobiol.
          <volume>46</volume>
<issue>2</issue>
<year>2012</year>
<fpage>495</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="pmid">22736079</pub-id>
</element-citation>
</ref>
<ref id="bib169">
<label>169</label>
<element-citation id="sref169" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdin</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Sarhan</surname>
<given-names>N.I.</given-names>
</name>
</person-group>
<article-title>Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of alpha-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity</article-title>
<source/>Neurosci. Res.
          <volume>71</volume>
<issue>4</issue>
<year>2011</year>
<fpage>387</fpage>
<lpage>395</lpage>
<pub-id pub-id-type="pmid">21889550</pub-id>
</element-citation>
</ref>
<ref id="bib170">
<label>170</label>
<element-citation id="sref170" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Role of nitric oxide in rotenone-induced nigro-striatal injury</article-title>
<source/>J. Neurochem.
          <volume>86</volume>
<issue>6</issue>
<year>2003</year>
<fpage>1338</fpage>
<lpage>1345</lpage>
<pub-id pub-id-type="pmid">12950443</pub-id>
</element-citation>
</ref>
<ref id="bib171">
<label>171</label>
<element-citation id="sref171" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Miranda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Narayan</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Nitrosative stress-induced Parkinsonian Lewy-like aggregates prevented through polyphenolic phytochemical analog intervention</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <volume>404</volume>
<issue>1</issue>
<year>2011</year>
<fpage>324</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="pmid">21130735</pub-id>
</element-citation>
</ref>
<ref id="bib172">
<label>172</label>
<element-citation id="sref172" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pubill</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Free radical production induced by methamphetamine in rat striatal synaptosomes</article-title>
<source/>Toxicol. Appl. Pharmacol.
          <volume>204</volume>
<issue>1</issue>
<year>2005</year>
<fpage>57</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="pmid">15781294</pub-id>
</element-citation>
</ref>
<ref id="bib173">
<label>173</label>
<element-citation id="sref173" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McColgan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tabrizi</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Huntington's disease: a clinical review</article-title>
<source/>Eur. J. Neurol.
          <volume>25</volume>
<issue>1</issue>
<year>2018</year>
<fpage>24</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">28817209</pub-id>
</element-citation>
</ref>
<ref id="bib174">
<label>174</label>
<element-citation id="sref174" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ni</surname>
<given-names>C.L.</given-names>
</name>
</person-group>
<article-title>Polyglutamine tract expansion increases S-nitrosylation of huntingtin and ataxin-1</article-title>
<source/>PloS One
          <volume>11</volume>
<issue>9</issue>
<year>2016</year>
<object-id pub-id-type="publisher-id">e0163359</object-id>
</element-citation>
</ref>
<ref id="bib175">
<label>175</label>
<element-citation id="sref175" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bates</surname>
<given-names>G.P.</given-names>
</name>
</person-group>
<article-title>Huntington disease</article-title>
<source/>Nat. Rev. Dis.Prim.
          <volume>1</volume>
<issue>1</issue>
<year>2015</year>
<fpage>15005</fpage>
<pub-id pub-id-type="pmid">27188817</pub-id>
</element-citation>
</ref>
<ref id="bib176">
<label>176</label>
<element-citation id="sref176" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deckel</surname>
<given-names>A.W.</given-names>
</name>
</person-group>
<article-title>Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington's disease transgenic mice</article-title>
<source/>Brain Res.
          <volume>939</volume>
<issue>1–2</issue>
<year>2002</year>
<fpage>76</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">12020853</pub-id>
</element-citation>
</ref>
<ref id="bib177">
<label>177</label>
<element-citation id="sref177" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarkar</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Complex inhibitory effects of nitric oxide on autophagy</article-title>
<source/>Mol. Cell.
          <volume>43</volume>
<issue>1</issue>
<year>2011</year>
<fpage>19</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">21726807</pub-id>
</element-citation>
</ref>
<ref id="bib178">
<label>178</label>
<element-citation id="sref178" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haun</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of dynamin-related protein 1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease</article-title>
<source/>Antioxidants Redox Signal.
          <volume>19</volume>
<issue>11</issue>
<year>2013</year>
<fpage>1173</fpage>
<lpage>1184</lpage>
</element-citation>
</ref>
<ref id="bib179">
<label>179</label>
<element-citation id="sref179" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamura</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>S-Nitrosylation of Drp1 links excessive mitochondrial fission to neuronal injury in neurodegeneration</article-title>
<source/>Mitochondrion
          <volume>10</volume>
<issue>5</issue>
<year>2010</year>
<fpage>573</fpage>
<lpage>578</lpage>
<pub-id pub-id-type="pmid">20447471</pub-id>
</element-citation>
</ref>
<ref id="bib180">
<label>180</label>
<element-citation id="sref180" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiernan</surname>
<given-names>M.C.</given-names>
</name>
</person-group>
<article-title>Amyotrophic lateral sclerosis</article-title>
<source/>Lancet
          <volume>377</volume>
<issue>9769</issue>
<year>2011</year>
<fpage>942</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="pmid">21296405</pub-id>
</element-citation>
</ref>
<ref id="bib181">
<label>181</label>
<element-citation id="sref181" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nowicka</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Risk factors and emerging therapies in amyotrophic lateral sclerosis</article-title>
<source/>Int. J. Mol. Sci.
          <volume>20</volume>
<issue>11</issue>
<year>2019</year>
</element-citation>
</ref>
<ref id="bib182">
<label>182</label>
<element-citation id="sref182" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oskarsson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gendron</surname>
<given-names>T.F.</given-names>
</name>
<name>
<surname>Staff</surname>
<given-names>N.P.</given-names>
</name>
</person-group>
<article-title>Amyotrophic lateral sclerosis: an update for 2018</article-title>
<source/>Mayo Clin. Proc.
          <volume>93</volume>
<issue>11</issue>
<year>2018</year>
<fpage>1617</fpage>
<lpage>1628</lpage>
<pub-id pub-id-type="pmid">30401437</pub-id>
</element-citation>
</ref>
<ref id="bib183">
<label>183</label>
<element-citation id="sref183" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>S-nitrosylated GAPDH mediates neuronal apoptosis induced by amyotrophic lateral sclerosis-associated mutant SOD1G93A</article-title>
<source/>Anim. Cell Syst.
          <volume>20</volume>
<issue>6</issue>
<year>2016</year>
<fpage>310</fpage>
<lpage>316</lpage>
</element-citation>
</ref>
<ref id="bib184">
<label>184</label>
<element-citation id="sref184" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schonhoff</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>S-nitrosothiol depletion in amyotrophic lateral sclerosis</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>103</volume>
<issue>7</issue>
<year>2006</year>
<fpage>2404</fpage>
<lpage>2409</lpage>
<pub-id pub-id-type="pmid">16461917</pub-id>
</element-citation>
</ref>
<ref id="bib185">
<label>185</label>
<element-citation id="sref185" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cereda</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Effect of nitric oxide on lymphocytes from sporadic amyotrophic lateral sclerosis patients: toxic or protective role?</article-title>
<source/>Neurol. Sci.
          <volume>27</volume>
<issue>5</issue>
<year>2006</year>
<fpage>312</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="pmid">17122939</pub-id>
</element-citation>
</ref>
<ref id="bib186">
<label>186</label>
<element-citation id="sref186" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atkin</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Endoplasmic reticulum stress and induction of the unfolded protein response in human sporadic amyotrophic lateral sclerosis</article-title>
<source/>Neurobiol. Dis.
          <volume>30</volume>
<issue>3</issue>
<year>2008</year>
<fpage>400</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="pmid">18440237</pub-id>
</element-citation>
</ref>
<ref id="bib187">
<label>187</label>
<element-citation id="sref187" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahtoniemi</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Mutant SOD1 from spinal cord of G93A rats is destabilized and binds to inner mitochondrial membrane</article-title>
<source/>Neurobiol. Dis.
          <volume>32</volume>
<issue>3</issue>
<year>2008</year>
<fpage>479</fpage>
<lpage>485</lpage>
<pub-id pub-id-type="pmid">18817872</pub-id>
</element-citation>
</ref>
<ref id="bib188">
<label>188</label>
<element-citation id="sref188" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massignan</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <volume>353</volume>
<issue>3</issue>
<year>2007</year>
<fpage>719</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="pmid">17196550</pub-id>
</element-citation>
</ref>
<ref id="bib189">
<label>189</label>
<element-citation id="sref189" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basso</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis</article-title>
<source/>PloS One
          <volume>4</volume>
<issue>12</issue>
<year>2009</year>
<object-id pub-id-type="publisher-id">e8130</object-id>
</element-citation>
</ref>
<ref id="bib190">
<label>190</label>
<element-citation id="sref190" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casoni</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis</article-title>
<source/>J. Biol. Chem.
          <volume>280</volume>
<issue>16</issue>
<year>2005</year>
<fpage>16295</fpage>
<lpage>16304</lpage>
<pub-id pub-id-type="pmid">15699043</pub-id>
</element-citation>
</ref>
<ref id="bib191">
<label>191</label>
<element-citation id="sref191" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>S-nitrosylated protein disulfide isomerase contributes to mutant SOD1 aggregates in amyotrophic lateral sclerosis</article-title>
<source/>J. Neurochem.
          <volume>124</volume>
<issue>1</issue>
<year>2013</year>
<fpage>45</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">23043510</pub-id>
</element-citation>
</ref>
<ref id="bib192">
<label>192</label>
<element-citation id="sref192" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldenberg</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Multiple sclerosis review</article-title>
<source/>P T
          <volume>37</volume>
<issue>3</issue>
<year>2012</year>
<fpage>175</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="pmid">22605909</pub-id>
</element-citation>
</ref>
<ref id="bib193">
<label>193</label>
<element-citation id="sref193" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Multiple sclerosis</article-title>
<source/>Lancet
          <volume>391</volume>
<issue>10130</issue>
<year>2018</year>
<fpage>1622</fpage>
<lpage>1636</lpage>
<pub-id pub-id-type="pmid">29576504</pub-id>
</element-citation>
</ref>
<ref id="bib194">
<label>194</label>
<element-citation id="sref194" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dobson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Giovannoni</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Multiple sclerosis - a review</article-title>
<source/>Eur. J. Neurol.
          <volume>26</volume>
<issue>1</issue>
<year>2019</year>
<fpage>27</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">30300457</pub-id>
</element-citation>
</ref>
<ref id="bib195">
<label>195</label>
<element-citation id="sref195" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Encinas</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Manganas</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Enikolopov</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Nitric oxide and multiple sclerosis</article-title>
<source/>Curr. Neurol. Neurosci. Rep.
          <volume>5</volume>
<issue>3</issue>
<year>2005</year>
<fpage>232</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="pmid">15865889</pub-id>
</element-citation>
</ref>
<ref id="bib196">
<label>196</label>
<element-citation id="sref196" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barcellos</surname>
<given-names>L.F.</given-names>
</name>
</person-group>
<article-title>Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis</article-title>
<source/>Ann. Neurol.
          <volume>55</volume>
<issue>6</issue>
<year>2004</year>
<fpage>793</fpage>
<lpage>800</lpage>
<pub-id pub-id-type="pmid">15174013</pub-id>
</element-citation>
</ref>
<ref id="bib197">
<label>197</label>
<element-citation id="sref197" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanwar</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Kanwar</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Krissansen</surname>
<given-names>G.W.</given-names>
</name>
</person-group>
<article-title>Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis</article-title>
<source/>Brain
          <volume>127</volume>
<issue>Pt 6</issue>
<year>2004</year>
<fpage>1313</fpage>
<lpage>1331</lpage>
<pub-id pub-id-type="pmid">15130951</pub-id>
</element-citation>
</ref>
<ref id="bib198">
<label>198</label>
<element-citation id="sref198" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Lassmann</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>The role of nitric oxide in multiple sclerosis</article-title>
<source/>Lancet Neurol.
          <volume>1</volume>
<issue>4</issue>
<year>2002</year>
<fpage>232</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="pmid">12849456</pub-id>
</element-citation>
</ref>
<ref id="bib199">
<label>199</label>
<element-citation id="sref199" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Acar</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Nitric oxide as an activity marker in multiple sclerosis</article-title>
<source/>J. Neurol.
          <volume>250</volume>
<issue>5</issue>
<year>2003</year>
<fpage>588</fpage>
<lpage>592</lpage>
<pub-id pub-id-type="pmid">12736739</pub-id>
</element-citation>
</ref>
<ref id="bib200">
<label>200</label>
<element-citation id="sref200" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danilov</surname>
<given-names>A.I.</given-names>
</name>
</person-group>
<article-title>Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis</article-title>
<source/>J. Neuroimmunol.
          <volume>136</volume>
<issue>1–2</issue>
<year>2003</year>
<fpage>112</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="pmid">12620649</pub-id>
</element-citation>
</ref>
<ref id="bib201">
<label>201</label>
<element-citation id="sref201" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rejdak</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis</article-title>
<source/>Neurology
          <volume>63</volume>
<issue>8</issue>
<year>2004</year>
<fpage>1439</fpage>
<lpage>1445</lpage>
<pub-id pub-id-type="pmid">15505162</pub-id>
</element-citation>
</ref>
<ref id="bib202">
<label>202</label>
<element-citation id="sref202" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hooper</surname>
<given-names>D.C.</given-names>
</name>
</person-group>
<article-title>Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>94</volume>
<issue>6</issue>
<year>1997</year>
<fpage>2528</fpage>
<lpage>2533</lpage>
<pub-id pub-id-type="pmid">9122229</pub-id>
</element-citation>
</ref>
<ref id="bib203">
<label>203</label>
<element-citation id="sref203" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions</article-title>
<source/>Am. J. Pathol.
          <volume>158</volume>
<issue>6</issue>
<year>2001</year>
<fpage>2057</fpage>
<lpage>2066</lpage>
<pub-id pub-id-type="pmid">11395383</pub-id>
</element-citation>
</ref>
<ref id="bib204">
<label>204</label>
<element-citation id="sref204" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bizzozero</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>DeJesus</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>T.A.</given-names>
</name>
</person-group>
<article-title>Exposure of rat optic nerves to nitric oxide causes protein S-nitrosation and myelin decompaction</article-title>
<source/>Neurochem. Res.
          <volume>29</volume>
<issue>9</issue>
<year>2004</year>
<fpage>1675</fpage>
<lpage>1685</lpage>
<pub-id pub-id-type="pmid">15453262</pub-id>
</element-citation>
</ref>
<ref id="bib205">
<label>205</label>
<element-citation id="sref205" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>G.P.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation and S-palmitoylation reciprocally regulate synaptic targeting of PSD-95</article-title>
<source/>Neuron
          <volume>71</volume>
<issue>1</issue>
<year>2011</year>
<fpage>131</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="pmid">21745643</pub-id>
</element-citation>
</ref>
<ref id="bib206">
<label>206</label>
<element-citation id="sref206" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ralat</surname>
<given-names>L.A.</given-names>
</name>
</person-group>
<article-title>Protective role of Cys-178 against the inactivation and oligomerization of human insulin-degrading enzyme by oxidation and nitrosylation</article-title>
<source/>J. Biol. Chem.
          <volume>284</volume>
<issue>49</issue>
<year>2009</year>
<fpage>34005</fpage>
<lpage>34018</lpage>
<pub-id pub-id-type="pmid">19808678</pub-id>
</element-citation>
</ref>
<ref id="bib207">
<label>207</label>
<element-citation id="sref207" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abrams</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Farooq</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of ApoE in Alzheimer's disease</article-title>
<source/>Biochemistry
          <volume>50</volume>
<issue>17</issue>
<year>2011</year>
<fpage>3405</fpage>
<lpage>3407</lpage>
<pub-id pub-id-type="pmid">21443265</pub-id>
</element-citation>
</ref>
<ref id="bib208">
<label>208</label>
<element-citation id="sref208" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tortosa</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>MAP1B regulates microtubule dynamics by sequestering EB1/3 in the cytosol of developing neuronal cells</article-title>
<source/>EMBO J.
          <volume>32</volume>
<issue>9</issue>
<year>2013</year>
<fpage>1293</fpage>
<lpage>1306</lpage>
<pub-id pub-id-type="pmid">23572079</pub-id>
</element-citation>
</ref>
<ref id="bib209">
<label>209</label>
<element-citation id="sref209" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sultana</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach</article-title>
<source/>Neurobiol. Dis.
          <volume>22</volume>
<issue>1</issue>
<year>2006</year>
<fpage>76</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="pmid">16378731</pub-id>
</element-citation>
</ref>
<ref id="bib210">
<label>210</label>
<element-citation id="sref210" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghavami</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Autophagy and apoptosis dysfunction in neurodegenerative disorders</article-title>
<source/>Prog. Neurobiol.
          <volume>112</volume>
<year>2014</year>
<fpage>24</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="pmid">24211851</pub-id>
</element-citation>
</ref>
<ref id="bib211">
<label>211</label>
<element-citation id="sref211" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitsumoto</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat</article-title>
<source/>Free Radic. Res.
          <volume>35</volume>
<issue>3</issue>
<year>2001</year>
<fpage>301</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="pmid">11697128</pub-id>
</element-citation>
</ref>
<ref id="bib212">
<label>212</label>
<element-citation id="sref212" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meneghetti</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Prions strongly reduce NMDA receptor S-nitrosylation levels at pre-symptomatic and terminal stages of prion diseases</article-title>
<source/>Mol. Neurobiol.
          <volume>56</volume>
<issue>9</issue>
<year>2019</year>
<fpage>6035</fpage>
<lpage>6045</lpage>
<pub-id pub-id-type="pmid">30710214</pub-id>
</element-citation>
</ref>
<ref id="bib213">
<label>213</label>
<element-citation id="sref213" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death</article-title>
<source/>Science
          <volume>297</volume>
<issue>5584</issue>
<year>2002</year>
<fpage>1186</fpage>
<lpage>1190</lpage>
<pub-id pub-id-type="pmid">12183632</pub-id>
</element-citation>
</ref>
</ref-list>
<ack id="ack0010">
<title>Acknowledgments</title>
<p>We thank Dr. Igor Khaliulin for his contribution in the discussion of this work.</p>
</ack>
</back>
</article>
</pmc-articleset>